Pharmacoeconomic evaluation of apixaban use for the treatment and prevention of venous thromboembolism in the general population and patients with oncological diseases

Authors: A. S. Kolbin, A. R. Kasimova, S. R. Gilyarevskiy

Source: Качественная клиническая практика, Vol 0, Iss 4, Pp 38-49 (2023)

Subject Terms: фармакоэкономический анализ, ишемический инсульт, апиксабан, венозные тромбоэмболические осложнения, дабигатран, прямые пероральные антикоагулянты, низкомолекулярные гепарины, 3. Good health, RS1-441, фибрилляция предсердий, Pharmacy and materia medica, ривароксабан, Medical technology, R855-855.5, тромбоэмболия лёгочной артерии, тромбоз глубоких вен, пероральные антикоагулянты

Access URL: https://doaj.org/article/6ff807e2571742b38079ad62f6a0f807

Possibility to use direct oral anticoagulants to prevent thromboembolic events in patients with COVID-19

Authors: V. A. Otdelenov, K. B. Mirzaev, D. A. Sychev

Source: Качественная клиническая практика, Vol 0, Iss 4S, Pp 18-22 (2020)

Subject Terms: RS1-441, 2. Zero hunger, 03 medical and health sciences, Pharmacy and materia medica, 0302 clinical medicine, covid-19, Medical technology, коронавирус, прямые пероральные антикоагулянты, R855-855.5, 3. Good health

Access URL: https://www.clinvest.ru/jour/article/download/519/527
https://doaj.org/article/c642c348f7d74c5f821007ddf6ae9220
https://www.clinvest.ru/jour/article/download/519/527
https://www.clinvest.ru/jour/article/view/519
https://cyberleninka.ru/article/n/vozmozhnost-primeneniya-pryamyh-peroralnyh-antikoagulyantov-dlya-profilaktiki-tromboembolicheskih-sobytiy-u-patsientov-s-covid-19
https://cyberleninka.ru/article/n/vozmozhnost-primeneniya-pryamyh-peroralnyh-antikoagulyantov-dlya-profilaktiki-tromboembolicheskih-sobytiy-u-patsientov-s-covid-19/pdf

New prospects for assessing the hemostasis system in atrial fibrillation and left atrial appendage thrombosis ; Возможности оценки системы гемостаза при фибрилляции предсердий и тромбозе ушка левого предсердия

Authors: Z. A. Gebekova, I. I. Ivanov, A. A. Kudrjavtseva, E. V. Kolpachkova, A. A. Sokolova, V. P. Sedov, D. A. Napalkov, З. А. Гебекова, И. И. Иванов, А. А. Кудрявцева, Е. В. Колпачкова, А. А. Соколова, В. П. Седов, Д. А. Напалков

Source: Aterotromboz = Atherothrombosis; Том 12, № 2 (2022); 103-112 ; Атеротромбоз; Том 12, № 2 (2022); 103-112 ; 2658-5952 ; 2307-1109 ; 10.21518/2307-1109-2022-2

Subject Terms: дабигатран, atrial fibrillation (AF), left atrial thrombosis, direct oral anticoagulants (DOACs), dabigatran, фибрилляция предсердий, тромбоз левого предсердия, прямые пероральные антикоагулянты

File Description: application/pdf

Relation: https://www.aterotromboz.ru/jour/article/view/289/302; Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J., Blomström-Lundqvist C. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373–498. https://doi.org/10.1093/eurheartj/ehaa612.; Durmaz E., Karpuz M.H., Bilgehan K., Ikitimur B., Ozmen E., Ebren C. et al. Left atrial thrombus in patients with atrial fibrillation and under oral anticoagulant therapy; 3-D transesophageal echocardiographic study. Int J Cardiovasc Imaging. 2020;36(6):1097–1103. https://doi.org/10.1007/s10554-020-01811-x.; Göldi T., Krisai P., Knecht S., Aeschbacher S., Spies F., Zeljkovic I. et al. Prevalence and Management of Atrial Thrombi in Patients With Atrial Fibrillation Before Pulmonary Vein Isolation. JACC Clin Electrophysiol. 2019;5(12):1406–1414. https://doi.org/10.1016/j.jacep.2019.09.003.; Кривошеев Ю.С., Башта Д.И., Красильникова С.Ю., Виленский Л.И., Колесников В.Н., Чуков С.З., Романов А.Б. Тромбоз ушка левого предсердия при фибрилляции предсердий – современное состояние проблемы. Вестник аритмологии. 2019;26(4):13–20. https://doi.org/10.35336/VA-2019-4-13-20.; Гебекова З.А., Иванов И.И., Асамбаева А., Скрипка А.И., Соколова А.А., Напалков Д.А., Вуймо Т.А. Тест «Тромбодинамика» в оценке риска тромбообразования у пациентов с фибрилляцией предсердий, получающих прямые оральные антикоагулянты. Рациональная фармакотерапия в кардиологии. 2022;18(5):544–552. https://doi.org/10.20996/1819-6446-2022-09-07.; Kolekar S., Munjewar Ch., Sharma S. Dabigatran for left ventricular thrombus. Indian Heart Journal. 2015;67:495–496. https://doi.org/10.1016/j.ihj.2015.06.010.; Vidal A., Vanerio G. Dabigatran and left atrial appendage thrombus. J Thromb Thrombolysis. 2012;34:545–547. https://doi.org/10.1007/s11239-012-0747-1.; Takasugi J., Yamagami H., Okata T., Toyoda K., Nagatsuka K. Dissolution of the Left Atrial Appendage Thrombus with Rivaroxaban Therapy. Cerebrovasc Dis. 2013;36:322–323. https://doi.org/10.1159/000354315.; Hammerstingl C., Pötzsch B., Nickenig G. Resolution of giant left atrial appendage thrombus with rivaroxaban. Thromb Haemost. 2013;109:583–584. https://doi.org/10.1160/TH12-11-0821.; Kawakami T., Kobayakawa H., Ohno H., Tanaka N., Ishihara H. Resolution of left atrial appendage thrombus with apixaban. Thromb J. 2013;11(1):26. https://doi.org/10.1186/1477-9560-11-26.; Yildirim E., Kalkan K., Ipek E., Demirelli S., Ermiş E. Successful resolution of left ventricular thrombus with apixaban treatment. Int J Cardiovasc Acad. 2016;2(2):57–58. https://doi.org/10.1016/j.ijcac.2015.12.004.; Lip G.Y., Hammerstingl C., Marin F., Cappato R., Meng I.L., Kirsch B. et al. Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J. 2016;178:126–134. https://doi.org/10.1016/j.ijcac.2015.12.004.; Zoppo F., Brandolino G., Berton A., Frigato N., Michieletto M., Zanocco A. et al. Predictors of left atrium appendage clot detection despite on-target warfarin prevention for atrial fibrillation. J Interv Card Electrophysiol. 2012;35(2):151–158. https://doi.org/10.1007/s10840-012-9707-0.; Кропачева Е.С., Панченко Е.П., Добровольский А.Б., Атауллаханова А.М., Быкова Е.С., Титаева Е.В., Атьков О.Ю. Длительная терапия непрямыми антикоагулянтами у больных с мерцательной аритмией без поражения клапанов сердца (проспективное наблюдение). Часть I. влияние 12-месячной терапии аценокумаролом на уровень Д-димера, частоту тромбоза и параметры гемодинамики в ушке левого предсердия. Кардиология. 2004;44(6):19–25. Режим доступа: https://pubmed.ncbi.nlm.nih.gov/15211343.; Kawabata M., Goya M., Sasaki T., Maeda S., Shirai Y., Nishimura T. et al. Left Atrial Appendage Thrombi Formation in Japanese Non-Valvular Atrial Fibrillation Patients During Anticoagulation Therapy – Warfarin vs. Direct Oral Anticoagulants. Circ J. 2017;81(5):645–651. https://doi.org/10.1253/circj.CJ-16-1089.; Баландина А.Б., Кольцова Е.М., Шибеко А.М., Купраш А.Д., Атауллаханов Ф.И. Тромбодинамика: новый подход к диагностике нарушений системы гемостаза. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2018;17(4):114–126. https://doi.org/10.24287/1726-1708-2018-17-4-114-126.; Vuimo T., Belikov E., Litinskaya O. Efficiency of Thrombodynamics for Analysis of Hemostasis in Case of Transitory Ischemic Attack after Radio-frequency Ablation in a Patient with Paroxysmal Atrial Fibrillation. Am J Med Case Rep. 2015;3(10):333–337. https://doi.org/10.12691/ajmcr-3-10-8.; Balandina A.N., Serebriyskiy I.I., Poletaev A.V., Polokhov D., Gracheva M., Koltsova E. et al. Thrombodynamics-A new global hemostasis assay for heparin monitoring in patients under the anticoagulant treatment. PloS ONE. 2018;13(6):е0199900. https://doi.org/10.1371/journal.pone.0199900.; Sinauridze E.I., Vuimo T.A., Tarandovskiy I.D., Ovsepyan R., Surov S., Korotina N. et al. Thrombodynamics, a new global coagulation test: Measurement of heparin efficiency. Talanta. 2018;180:282–291. https://doi.org/10.1016/j.talanta.2017.12.055.; Рубаненко А.О., Рубаненко О.А., Дьячков В.А., Щукин Ю.В. Роль D-димера в прогнозировании риска инсульта у больных с фибрилляцией предсердий. Гематология и трансфузиология. 2022;67(2):261–266. https://doi.org/10.35754/0234-5730-2022-67-2-261-266.; https://www.aterotromboz.ru/jour/article/view/289

Availability: https://www.aterotromboz.ru/jour/article/view/289
https://doi.org/10.21518/2307-1109-2022-12-2-103-112

Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art ; Клинически значимые лекарственные взаимодействия прямых пероральных антикоагулянтов: современное состояние вопроса

Authors: S. R. Gilyarevsky, С. Р. Гиляревский

Source: Rational Pharmacotherapy in Cardiology; Vol 18, No 3 (2022); 332-341 ; Рациональная Фармакотерапия в Кардиологии; Vol 18, No 3 (2022); 332-341 ; 2225-3653 ; 1819-6446

Subject Terms: дабигатран, direct oral anticoagulants, apixaban, rivaroxaban, dabigatran, прямые пероральные антикоагулянты, апиксабан, ривароксабан

File Description: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2756/2322; Sarah S. The pharmacology and therapeutic use of dabigatran etexilate. J Clin Pharmacol. 2013;53(1):113. DOI:10.1177/0091270011432169.; Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008;6(5):820-9. DOI:10.1111/j.15387836.2008.02939.x.; Chan NC, Hirsh J, Ginsberg JS, Eikelboom JW. Betrixaban (PRT054021): pharmacology, dose selection and clinical studies. Future Cardiol. 2014;10(1):43-52. DOI:10.2217/fca.13.98.; Corsini A, Ferri N, Proietti M, Boriani G. Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice. Drugs. 2020;80(11):1065-83. DOI:10.1007/s40265-020-01328-6.; Kvasnicka T, Malikova I, Zenahlikova Z, et al. Rivaroxaban - Metabolism, Pharmacologic Properties and Drug Interactions. Curr Drug Metab. 2017;18(7):636-42. DOI:10.2174/1389200218666170518165443.; Foerster KI, Hermann S, Mikus G, Haefeli WE. Drug-Drug Interactions with Direct Oral Anticoagulants. Clin Pharmacokinet. 2020;59(8):967-80. DOI:10.1007/s40262-020-00879-x.; Connolly SJ, Milling TJ Jr, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375(12):1131-41. DOI:10.1056/NEJMoa1607887.; Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med. 2017;377(5):431-41. DOI:10.1056/NEJMoa1707278.; Reilly PA, Lehr T, Haertter S, et al.; RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63(4):321-8. DOI:10.1016/j.jacc.2013.07.104.; Ruff CT, Giugliano RP, Braunwald E, et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015;385(9984):2288-95. DOI:10.1016/S0140-6736(14)61943-7.; Herink MC, Zhuo YF, Williams CD, DeLoughery TG. Clinical Management of Pharmacokinetic Drug Interactions with Direct Oral Anticoagulants (DOACs). Drugs. 2019;79(15):1625-34. DOI:10.1007/s40265-019-01183-0.; Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. DOI:10.1056/NEJMoa0905561. Erratum in: N Engl J Med. 2010;363(19):1877.; Granger CB, Alexander JH, McMurray JJ, et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. DOI:10.1056/NEJMoa1107039.; Giugliano RP, Ruff CT, Braunwald E, et al.; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-104. DOI:10.1056/NEJMoa1310907.; Patel MR, Mahaffey KW, Garg J, et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91. DOI:10.1056/NEJMoa1009638.; Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104(3):633-641. DOI:10.1160/th10-01-0066.; Leil TA, Feng Y, Zhang L, et al. Quantification of apixaban’s therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. Clin Pharmacol Ther. 2010;88(3):375-382. DOI:10.1038/clpt.2010.106.; Sakaguchi T, Osanai H, Murase Y, et al. Monitoring of anti-Xa activity and factors related to bleeding events: a study in Japanese patients with nonvalvular atrial fibrillation receiving rivaroxaban. J Cardiol. 2017;70(3):244-9. DOI:10.1016/j.jjcc.2016.11.013.; Carnicelli AP, Hong H, Connolly SJ, et al.; COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) Investigators. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network MetaAnalyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. Circulation. 2022;145(4):242-55. DOI:10.1161/CIRCULATIONAHA.121.056355.; Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-962. DOI:10.1016/S0140-6736(13)62343-0.; Almutairi AR, Zhou L, Gellad WF, et al. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses. Clin Ther. 2017;39(7):1456-78.e36. DOI:10.1016/j.clinthera.2017.05.358.; Piccini JP, Hellkamp AS, Washam JB, et al. Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. Circulation. 2016;133(4):352-60. DOI:10.1161/CIRCULATIONAHA.115.018544.; Focks JJ, Brouwer MA, Wojdyla DM, et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ. 2016;353:i2868. DOI:10.1136/bmj.i2868.; Harskamp RE, Teichert M, Lucassen WAM, et al. Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation. Cardiovasc Drugs Ther. 2019;33(5):615-23. DOI:10.1007/s10557-019-06907-8.; Stöllberger C, Finsterer J. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban. Herz. 2015;40 Suppl 2:140-5. DOI:10.1007/s00059-014-4188-9.; Chang SH, Chou IJ, Yeh YH, et al. Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation. JAMA. 2017;318(13):1250-9. DOI:10.1001/jama.2017.13883.; Rodrigues AD. Prioritization of clinical drug interaction studies using in vitro cytochrome P450 data: proposed refinement and expansion of the "rank order" approach. Drug Metab Lett. 2007;1(1):31-5. DOI:10.2174/187231207779814247.; Wiggins BS, Dixon DL, Neyens RR, et al. Select Drug-Drug Interactions With Direct Oral Anticoagulants. J Am Coll Cardiol. 2020;75:1341-50. DOI:10.1016/j.jacc.2019.12.068.; Cheong EJY, Goh JJN, Hong Y, et al. Rivaroxaban With and Without Amiodarone in Renal Impairment. J Am Coll Cardiol. 2018;71(12):1395-7. DOI:10.1016/j.jacc.2018.01.044.; Flaker G, Lopes RD, Hylek E, et al.; ARISTOTLE Committees and Investigators. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. J Am Coll Cardiol. 2014;64(15):1541-50. DOI:10.1016/j.jacc.2014.07.967.; Steffel J, Giugliano RP, Braunwald E, et al. Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2015;36(33):2239-45. DOI:10.1093/eurheartj/ehv201.; Steinberg BA, Hellkamp AS, Lokhnygina Y, et al.; ROCKET AF Steering Committee and Investigators. Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial. Heart Rhythm. 2014;11(6):925-32. DOI:10.1016/j.hrthm. 2014.03.006.; Friberg L. Safety of apixaban in combination with dronedarone in patients with atrial fibrillation. Int J Cardiol. 2018;264:85-90. DOI:10.1016/j.ijcard.2018.02.055.; Härtter S, Sennewald R, Nehmiz G, Reilly P. Oral bioavailability of dabigatran etexilate (Pradaxa(®) ) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol. 2013;75(4):1053-62. DOI:10.1111/j.1365-2125.2012.04453.x.; Frost C, Wang J, Nepal S, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013;75(2):47687. DOI:10.1111/j.1365-2125.2012.04369.x.; Kim M, Son H, Noh K, et al. Effects of Verapamil and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban. Pharmaceutics. 2019;11(3):133. DOI:10.3390/pharmaceutics11030133.; Greenblatt DJ, Patel M, Harmatz JS, et al. Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection. J Clin Pharmacol. 2018;58(4):533-540. DOI:10.1002/jcph.1040.; Bartlett JW, Renner E, Mouland E, et al. Clinical Safety Outcomes in Patients With Nonvalvular Atrial Fibrillation on Rivaroxaban and Diltiazem. Ann Pharmacother. 2019;53(1):21-7. DOI:10.1177/1060028018795140.; Wiggins BS, Northup A, Johnson D, Senfield J. Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin. Pharmacotherapy. 2016;36(2):e5-7. DOI:10.1002/phar.1698.; King PK, Stump TA, Walkama AM, et al. Management of Phenobarbital and Apixaban Interaction in Recurrent Cardioembolic Stroke. Ann Pharmacother. 2018;52(6):605-6. DOI:10.1177/1060028018759938.; Steinberg BA, Shrader P, Thomas L, et al.; ORBIT-AF Investigators and Patients. Off-Label Dosing of NonVitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. J Am Coll Cardiol. 2016;68(24):2597-604. DOI:10.1016/j.jacc.2016.09.966.; Ruiz Ortiz M, Muñiz J, RañaMíguez P, et al.; FANTASIIA study investigators. Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry. Europace. 2018;20(10):1577-83. DOI:10.1093/europace/eux316.; Pattullo CS, Barras M, Tai B, et al. New oral anticoagulants: appropriateness of prescribing in real-world setting. Intern Med J. 2016;46(7):812-8. DOI:10.1111/imj.13118.; Okumura Y, Yokoyama K, Matsumoto N, et al.; The Sakura Af Registry Investigators. Current use of direct oral anticoagulants for atrial fibrillation in Japan: Findings from the SAKURA AF Registry. J Arrhythm. 2017;33(4):289-96. DOI:10.1016/j.joa.2016.11.003.; Yao X, Shah ND, Sangaralingham LR, et al. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. J Am Coll Cardiol. 2017;69(23):2779-90. DOI:10.1016/j.jacc.2017.03.600.; Barnes GD, Nallamothu BK, Sales AE, Froehlich JB. Reimagining Anticoagulation Clinics in the Era of Direct Oral Anticoagulants. Circ Cardiovasc Qual Outcomes. 2016;9(2):182-5. DOI:10.1161/CIRCOUTCOMES. 115.002366.; Raval AN, Cigarroa JE, Chung MK, et al. Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association. Circulation. 2017;135(10):e604-e633. DOI:10.1161/CIR.0000000000000477.; https://www.rpcardio.com/jour/article/view/2756

Availability: https://www.rpcardio.com/jour/article/view/2756
https://doi.org/10.20996/1819-6446-2022-05-02

Проблемы выбора антикоагулянта для вторичной профилактики инсульта у пациентов с фибрилляцией предсердий ; Problems of selecting an anticoagulant for secondary stroke prevention in patients with atrial fibrillation

Authors: Gusev, V. V., Lvova, O. A., Shamalov, N. A., Гусев, В. В., Львова, О. А., Шамалов, Н. А.

Subject Terms: SCHEMIC STROKE, ATRIAL FIBRILLATION, SECONDARY PREVENTION, DIRECT ORAL ANTICOAGULANTS, ИШЕМИЧЕСКИЙ ИНСУЛЬТ, ФИБРИЛЛЯЦИЯ ПРЕДСЕРДИЙ, ВТОРИЧНАЯ ПРОФИЛАКТИКА, ПРЯМЫЕ ПЕРОРАЛЬНЫЕ АНТИКОАГУЛЯНТЫ

File Description: application/pdf

Relation: Scopus; Гусев В.В., Львова О.А., Шамалов Н.А. Проблемы выбора антикоагулянта для вторичной профилактики инсульта у пациентов с фибрилляцией предсердий. Кардиоваскулярная терапия и профилактика. 2021;20(6):3044.; http://elib.usma.ru/handle/usma/7216

Availability: http://elib.usma.ru/handle/usma/7216

Antithrombotic Management for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention ; Антитромботическая терапия у пациентов с фибрилляцией предсердий при чрескожных коронарных вмешательствах

Authors: A. Panov V., А. Панов В.

Source: Rational Pharmacotherapy in Cardiology; Vol 17, No 4 (2021); 628-637 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 4 (2021); 628-637 ; 2225-3653 ; 1819-6446

Subject Terms: чрескожное коронарное вмешательство, фибрилляция предсердий, варфарин, прямые пероральные антикоагулянты, двойная и тройная антитромботическая терапия

File Description: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2546/2215; Nabauer M, Gerth A, Limbourg T, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009;11(4):423-34. DOI:10.1093/europace/eun369.; Steinberg BA, Kim S, Piccini JP, et al. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Circulation. 2013;128(7):721-8. DOI:10.1161/CIRCULATIONAHA.113.002927.; Fox KAA, Velentgas P, Camm AJ, et al. Outcomes associated with oral anticoagulants plus antiplatelets in patients with newly diagnosed atrial fibrillation. JAMA Netw Open. 2020;3(2):e200107. DOI:10.1001/jamanetworkopen.2020.0107.; Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26(22):2422-34. DOI:10.1093/eurheartj/ehi505; Steffel1 Y, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021 Apr 25;euab065. DOI:10.1093/europace/euab065.; Depta JP, Cannon CP, Fonarow GC, et al. Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes. Am J Cardiol. 2009;104(9):1171-8. DOI:10.1016/j.amjcard.2009.06.027.; Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-17. DOI:10.1056/NEJMoa1107039.; Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903-12. DOI:10.1016/S01406736(06)68845-4.; Leon MB, Baim DS, Popma JJ, et al., Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med. 1998; 339(23):1665-71. DOI:10.1056/NEJM199812033392303.; Dentali F, Douketis JD, Lim W, et al. Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med. 2007;167(2):117-24. DOI:10.1001/archinte.167.2.117.; Hansen ML, Sorensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170(16):1433-41. DOI:10.1001/archinternmed.2010.271.; Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380(16):1509-24. DOI:10.1056/NEJMoa1817083.; Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381(9872):1107-15. DOI:10.1016/S01406736(12)62177-1.; Gibson CM, Mehran R, Bode C, et al. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J. 2015;169(4):472-8.e5. DOI:10.1016/j.ahj.2014.12.006.; Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(16):1513-24. DOI:10.1056/NEJMoa1708454.; Vranckx P, Valgimigli M, Eckardt L, et al. Edoxabanbased versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients withatrial fibrillation (ENTRUSTAF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394(10206):1335-43. DOI:10.1056/NEJMoa1708454.; Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013;127(5):634-40. DOI:10.1161/CIRCULATIONAHA.112.115386.; Faxon DP, Eikelboom JW, Berger PB, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summa-ry. Circ Cardiovasc Interv. 2011;4(5):522-34. DOI:10.1161/CIRCINTERVENTIONS.111.965186.; Paikin JS, Wright DS, Crowther MA, et al. Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation. 2010;121(18):2067-70. DOI:10.1161/CIRCULATIONAHA.109.924944.; Steg PG, Huber K, Andreotti F, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2011;32(15):1854-64. DOI:10.1093/eurheartj/ehr204.; Fiedler K.A., Maeng M., Mehilli J., et al. Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. J Am Coll Cardiol. 2015;65(16):1619-29. DOI:10.1016/j.jacc.2015.02.050.; Фибрилляция и трепетание предсердий. Рекомендации Российского Кардиологического Общества (2020) [цитировано 30.06.2021. Доступно на: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_FP_TP.pdf.; Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российское кардиологическое общество, Ассоциация сердечно-сосудистых хирургов России. Российский Кардиологический Журнал. 2020;25(11):4103. DOI:10.15829/1560-4071-2020-4103.; Острый коронарный синдром без подъема сегмента ST электрокардиограммы. Рекомендации Российского Кардиологического Общества (2020). Российский Кардиологический Журнал. 2020;26(4):4449. DOI:10.15829/1560-4071-2021-4449.; Стабильная ишемическая болезнь сердца. Рекомендации Российского Кардиологического Общества (2020). Российский Кардиологический Журнал. 2020;25(11):201-51. DOI:10.15829/1560-4071-2020-4076.; Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. DOI:10.1093/eurheartj/ehaa612.; Kumbhani DJ, Cannon CP, Beavers CJ, et al. 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020;77(5):629-58. DOI:10.1016/j.jacc.2020.09.011.; Lopes RD, Leonardi S, Wojdyla DM, et al. Stent thrombosis in patients with atrial fibrillation undergoing coronary stenting in the AUGUSTUS trial. Circulation. 2019;141(9):781-3. DOI:10.1161/CIRCULATIONAHA.119.044584.; Angiolillo DJ, Goodman SG, Bhatt DL, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention. Circulation. 2018;138(5):527-36. DOI:10.1161/CIRCULATIONAHA.120.050438.; Lip GYH, Collet JP, Haude M, et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the EHRA, EAPCI, ACCA endorsed by the HRS, APHRS, LAHRS, CASSA. Europace. 2019;21(2):192-3. DOI:10.1093/europace/euy174.; Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012;367(22):2100-9. DOI:10.1056/NEJMoa1209979.; Price MJ, Berger PB, Teirstein PS, et al. Standardvs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305(11):1097-105. DOI:10.1001/jama.2011.290.; Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol. 2012;59(24):2159-64. DOI:10.1016/j.jacc.2012.02.026.; Claassens DMF, Vos GJA, Bergmeijer TO, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med. 2019;381(17):1621-31. DOI:10.1056/NEJMoa1907096.; Yasuda S, Kaikita K, Akao M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019;381():1103-13. DOI:10.1056/NEJMoa1904143.; Matsumura-Nakano Y, Shizuta S, Komasa A, et al. Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation. Circulation. 2019;139(5):604-16. DOI:10.1161/CIRCULATIONAHA.118.036768.; Berry NC, Mauri L, Steg PG, et al. Effect of lesion complexity and clinical risk factors on the efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: a subgroup analysis from the REDUAL PCI trial. Circ Cardiovasc Interv. 2020;13(4):e008349. DOI:10.1161/CIRCINTERVENTIONS.119.008349.; Rossini R, Musumeci G, Lettieri C, et al. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol. 2008;102(12):1618-23. DOI:10.1016/j.amjcard.2008.08.021.; Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebocontrolled, crossover comparison studies. Clin Pharmacol Ther. 2011;89(1):65-74. DOI:10.1038/clpt.2010.219.; Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9):937-44. DOI:10.1001/jama.2009.261.; Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909-17. DOI:10.1056/NEJMoa1007964.; Tada T, Byrne RA, Simunovic I, et al. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents,and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC Cardiovasc Interv. 2013;6(12):1267-74. DOI:10.1016/j.jcin.2013.06.015.; Rubboli A, Lip GYH. Algorithm for the management of antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention: an updated proposal based on efficacy considerations. Eur Heart J Cardiovasc Pharmacother. 2020;6(3):197-8. DOI:10.1093/ehjcvp/pvaa003.; Baker NC, O’Connell EW, Htun WW, et al. Safety of coronary angiography andpercutaneous coronary intervention via the radial versus femoral route inpatients on uninterrupted oral anticoagulation with warfarin. Am Heart J. 2014;168(4):537-44. DOI:10.1016/j.ahj.2014.06.016.; Chongprasertpon N, Zebrauskaite A, Coughlan JJ, et al. Performing diagnostic radial access coronary angiog-raphy on uninterrupted direct oral anticoagulant therapy: a prospective analysis. Open Heart. 2019;6(1):e0010. DOI:10.1136/openhrt-2019-001079.; Giustino G, Chieffo A, Palmerini T et al. Efficacy and safety of dual antiplatelet therapy after complex PCI. J Am Coll Cardiol. 2016;68(17):1851-64. DOI:10.1016/j.jacc.2016.07.760.; Neumann FJ, Sousa-Uva M, Ahlsson A, et al. ESC Scientific Document Group. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87-165. DOI:10.1093/eurheartj/ehy394.; Knuuti J, Wijns W, Saraste A, Capodanno D, et al. ESC Scientific Document Group. 2019 ESC guidelines for the diagnosis a management of chronic coronary syndromes. Eur Heart J. 2020;41(3):40777. DOI:10.1093/eurheartj/ehz425; Wallentin L, Becker RC, Budaj A, et al. PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-57. DOI:10.1056/NEJMoa0904327.; Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-15. DOI:10.1056/NEJMoa0706482.; Jackson LR, Ju C, Zettler M, Messenger JC, et al. Outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention receiving an oral anticoagulant and dual antiplatelet therapy: a comparison of clopidogrel versus prasugrel from the TRANSLATE-ACS study. ACC Cardiovasc Interv. 2015;8(14):1880-9. DOI:10.1016/j.jcin.2015.08.018.; Valgimigli M, Bueno H, Byrne RA, et al. ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the ESC and of the EACTS. Eur Heart J. 2018;39(3):213-60. DOI:10.1093/eurheartj/ehx419.; Lau WCY, Douglas IJ, Wong ICK, et al. Thromboembolic, bleeding, and mortalityrisks among patients with nonvalvular atrial fibrillation treated with dual antiplatelet therapy versus oral anticoagulants: a population-based study. Heart Rhythm. 2020;17(1):33-40. DOI:10.1016/j.hrthm.2019.07.034.; Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin inpatients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-62. DOI:10.1016/S0140-6736(13)62343-0.; Genereux P, Giustino G, Witzenbichler B, et al. Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention. J Am Coll Cardiol. 2015;66(9):1036-45. DOI:10.1016/j.jacc.2015.06.1323.; ten Berg JM, de Veer A, Oldgren J, Steg PG, et al. RE-DUAL PCI Steering Committee and Investigators. Switching of oral anticoagulation therapy after PCI in patients with atrial fibrillation: the RE-DUAL PCI trial subanalysis. JACC Cardiovasc Interv. 2019;12(23):2331-41. DOI:10.1016/j.jcin.2019.08.039.; Rubboli A, Valgimigli M, Capodanno D, et al. Choices in antithrombotic management for patients with atrial fibrillation undergoing percutaneous coronary intervention: questions (and answers) in chronological sequence. Eur Heart J – Cardiovascular Pharmacotherapy. 2021;7(1):68-73. DOI:10.1093/ehjcvp/pvaa047.; Rubboli A, Lisi M. After the AUGUSTUS trial, should apixaban be the only directoral anticoagulant to be used in triple therapy in atrial fibrillation patients under-going percutaneous coronary intervention? Cardiovasc Drugs Ther. 2019;33(4):499-500. DOI:10.1007/s10557-019-06886-w.; Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis. 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 suppl):e326S-e350S. DOI:10.1378/chest.11-2298.; Eikelboom JW, Connolly S J, Bosch J, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 2017; 377(14):1319-1330. DOI:10.1056/NEJMoa1709118.; Mega J, Braunwald E, Wiviott S, et al. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. N Engl J Med. 2012;366(1):9-19. DOI:10.1056/NEJMoa1112277.; Pradaxa. Summary of product characteristics. European Medicines Agency DSoPC [cited by Jun 30, 2021. Available from: https://www.ema.europa.eu/en/documents/product-information/pradaxa-epar-product-information_en.pdf.; van Es RF, Jonker JJ, Verheugt FW, et al. Antithrombotics in the Secondary Prevention of Events in CoronaryThrombosis-2 (ASPECT-2) Research Group. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet. 2002;360(9327):109-13. DOI:10.1016/S0140-6736(02)09409-6.; Hurlen M, Abdelnoor M, Smith P et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347(13):969-74. DOI:10.1056/NEJMoa020496.; Hamon M, Lemesle G, Tricot O, et al. Incidence, source, determinants, and prognostic im-pact of major bleeding in outpatients with stable coronary artery disease. J Am Coll Cardiol. 2014;64(14):1430-6. DOI:10.1016/j.jacc.2014.07.957.; Yasuda S, Kaikita K, Akao M, et al. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. N Engl J Med. 2019;381(12):1103-13. DOI:10.1056/NEJMoa1904143.; https://www.rpcardio.com/jour/article/view/2546

Availability: https://www.rpcardio.com/jour/article/view/2546
https://doi.org/10.20996/1819-6446-2021-07-02

Approaches to Assessing the Quality of Observational Studies of Clinical Practice Based on the Big Data Analysis ; Подходы к оценке качества наблюдательных исследований клинической практики, основанных на анализе «больших данных»

Authors: S. Gilyarevsky R., С. Гиляревский Р.

Source: Rational Pharmacotherapy in Cardiology; Vol 17, No 4 (2021); 584-593 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 4 (2021); 584-593 ; 2225-3653 ; 1819-6446

Subject Terms: clinical practice studies, big data, pharmacoepidemiological studies, direct oral anticoagulants, исследования реальной клинической практики, «большие данные», фармакоэпидемиологические исследования, прямые пероральные антикоагулянты

File Description: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2541/2210; U.S. Food and Drug Administration. Framework for FDA’s realworld evidence programa (2018) [cited by Jun 30, 2021. Available from: https://www.fda.gov/media/120060/download.; Berger ML, Doban V. Big data, advanced analytics and the future of comparative effectiveness research. J Comp Eff Res. 2014;3(2):167-76. DOI:10.2217/cer.14.2.; Okada M. Big data and real-world data-based medicine in the management of hypertension. Hypertens Res. 2021;44(2):147-53. DOI:10.1038/s41440-020-00580-3.; Hay SI, George DB, Moyes CL, Brownstein JS. Big data opportunities for global infectious disease surveillance. PLoS Med. 2013;10(4):e1001413. DOI:10.1371/journal.pmed.1001413.; Ola O, Sedig K. The challenge of big data in public health: an opportunity for visual analytics. Online J Public Health Inform. 2014;5(3):223. DOI:10.5210/ojphi.v5i3.4933.; Fanaroff AC, Califf RM, Lopes RD. New Approaches to Conducting Randomized Controlled Trials. J Am Coll Cardiol 2020;75:556-9. DOI:10.1016/j.jacc.2019.11.043.; Murray KW, Duggan A. Understanding Confounding in Research Pediatr Rev. 2010;31(3):124-6. DOI:10.1542/pir.31-3-124.; Meuli L, Dick F. Understanding Confounding in Observational Studies. Eur J Vasc Endovasc Surg. 2018;55(5):737. DOI:10.1016/j.ejvs.2018.02.028.; Fanaroff AC, Califf RM, Windecker S, et al. Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018. JAMA. 2019;321:1069-80. DOI:10.1001/jama.2019.1122.; Гиляревский С.Р., Гаврилов Д.В., Гусев А.В. Результаты ретроспективного анализа записей электронных амбулаторных медицинских карт пациентов с хронической сердечной недостаточностью: первый российский опыт. Российский Кардиологический Журнал. 2021;26(5):4502. DOI:10.15829/1560-4071-2021-4502.; Althubaiti A. Information bias in health research: definition, pitfalls, and adjustment methods. J Multidiscip Healthc. 2016;9:211-7. DOI:10.2147/JMDH.S104807.; Matsumoto S, Fukui M, Hamaguchi M, et al. Is home blood pressure reporting in patients with type 2 diabetes reliable? Hypertens Res. 2014;37(8):741-5. DOI:10.1038/hr.2014.66.; Schneeweiss S, Rassen JA, Glynn RJ, et al. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20(4):512-22. DOI:10.1097/EDE.0b013e3181a663cc.; Cox DR, Kartsonaki C, Keogh RH. Big data: Some statistical issues. Stat Probab Lett. 2018;136:1115. DOI:10.1016/j.spl.2018.02.015.; Beaulieu-Jones BK, Finlayson SG, Yuan W, et al. Examining the Use of Real-World Evidence in the Regulatory Process. Clin Pharmacol Ther. 2020;107(4):843-52. DOI:10.1002/cpt.1658.; Langan SM, Schmidt SA, Wing K, et al. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ. 2018;363:k3532. DOI:10.1136/bmj.k3532.; Benchimol EI, Smeeth L, Guttmann A, et al.; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med. 2015;12(10):e1001885. DOI:10.1371/journal.pmed.1001885.; von Elm E, Altman DG, Egger M, et al.; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453-7. DOI:10.1016/S0140-6736(07)61602-X.; Hemkens LG, Benchimol EI, Langan SM, et al. The reporting of studies using routinely collected health data was often insufficient. J Clin Epidemiol. 2016;79:104-11. DOI:10.1016/j.jclinepi.2016.06.005.; Dreyer NA, Schneeweiss S, McNeil BJ, et al.; GRACE Initiative. GRACE principles: recognizing highquality observational studies of comparative effectiveness. Am J Manag Care. 2010;16(6):467-71.; European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Guide on methodological standards in pharmacoepidemiology (2011) [cited by Jun 30, 2021. Available from: www.encepp.eu/standards_and_guidances/methodologicalGuide.shtml.; Blake KV, Devries CS, Arlett P, et al.; for the European Network of Centres for Pharmacoepidemiology Pharmacovigilance. Increasing scientific standards, independence and transparency in post-authorisation studies: the role of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Pharmacoepidemiol Drug Saf. 2012;21(7):690-6. DOI:10.1002/pds.3281.; Franklin JM, Schneeweiss S. When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials? Clin Pharmacol Ther. 2017;102(6):924-33. DOI:10.1002/cpt.857.; Schneeweiss S. Improving therapeutic effectiveness and safety through big healthcare data. Clin Pharmacol Ther. 2016;99(3):262-5. DOI:10.1002/cpt.316; Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-World Evidence What Is It and What Can It Tell Us? N Engl J Med. 2016;375(23):2293-7. DOI:10.1056/NEJMsb1609216.; Guimarães PO, Krishnamoorthy A, Kaltenbach LA, et al. Accuracy of Medical Claims for Identifying Cardiovascular and Bleeding Events After Myocardial Infarction: A Secondary Analysis of the TRANSLATE-ACS Study. JAMA Cardiol. 2017;2(7):750-7. DOI:10.1001/jamacardio.2017.1460.; Anglemyer A, Horvath HT, Bero L. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. In: The Cochrane Collaboration, ed. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2014 [cited by Jun 30, 2021. Available from: http://doi.wiley.com/10.1002/14651858.MR000034.pub2. Accessed May 12, 2016.; Hemkens LG, Contopoulos-Ioannidis DG, Ioannidis JPA. Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: meta-epidemiological survey. BMJ. 2016;352:i493. DOI:10.1136/bmj.i493.; Dahabreh IJ, Sheldrick RC, Paulus JK, et al. Do observational studies using propensity score methods agree with randomized trials? A systematic comparison of studies on acute coronary syndromes. Eur Heart J. 2012;33(15):1893-901. DOI:10.1093/eurheartj/ehs114.; Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med. 1991;325(11):756-62. DOI:10.1056/NEJM199109123251102.; Rossouw JE, Anderson GL, Prentice RL, et al.; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):32133. DOI:10.1001/jama.288.3.321.; Grodstein F, Manson JE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. a prospective, observational study. Ann Intern Med. 2001;135(1):1-8. DOI:10.7326/0003-4819-135-1-200107030-00003.; Hernán MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008;19(6):766-79. DOI:10.1097/EDE.0b013e3181875e61.; Goodman SN, Schneeweiss S, Baiocchi M. Using Design Thinking to Differentiate Useful From Misleading Evidence in Observational Research. JAMA. 2017;317(7):705-7. DOI:10.1001/jama.2016.19970.; Schneeweiss S, Seeger JD, Landon J, Walker AM. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med. 2008;358(8):771-83. DOI:10.1056/NEJMoa0707571.; Fergusson DA, Hébert PC, Mazer CD, et al.; BART Investigators. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008;358(22):2319-31. DOI:10.1056/NEJMoa0802395.; Agoritsas T, Merglen A, Shah ND, et al. Adjusted Analyses in Studies Addressing Therapy and Harm: Users' Guides to the Medical Literature. JAMA. 2017;317(7):748-59. DOI:10.1001/jama.2016.20029.; ISPOR Membership profile [cited by May 12, 2021. Available from: URL: https://www.ispor.org.; Proietti M, Romanazzi I, Romiti GF, et al. Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis. Stroke. 2018;49(1):98-106. DOI:10.1161/STROKEAHA.117.018395.; Escobar C, MartÍ-Almor J, Pérez Cabeza A, MartÍnez-Zapata MJ. Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis. Rev Esp Cardiol (Engl Ed). 2019;72(4):305-16. DOI:10.1016/j.rec.2018.03.009.; https://www.rpcardio.com/jour/article/view/2541

Availability: https://www.rpcardio.com/jour/article/view/2541
https://doi.org/10.20996/1819-6446-2021-08-01

Off-Label Medicines Use: Complex Problem of Modern Clinical Practice ; Назначение лекарственных препаратов по показаниям, не указанным в инструкции («off-label»): сложная проблема современной клинической практики

Authors: S. Gilyarevskiy R., С. Гиляревский Р.

Source: Rational Pharmacotherapy in Cardiology; Vol 16, No 2 (2020); 324-334 ; Рациональная Фармакотерапия в Кардиологии; Vol 16, No 2 (2020); 324-334 ; 2225-3653 ; 1819-6446

Subject Terms: off-label use, on-label use, direct oral anticoagulants, ivabradine, apixaban, rivaroxaban, назначения off-label, назначения on-label, прямые пероральные антикоагулянты, ивабрадин, апиксабан, ривароксабан

File Description: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2181/1974; Приказ Минздрава России (Министерство здравоохранения РФ) от 14 января 2019 г. №4н «Об утверждении порядка назначения лекарственных препаратов, форм рецептурных бланков на лекарственные препараты, порядка оформления указанных бланков, их учета и хранения» Опубликован на официальном интернет-портале правовой информации 27.03.19 г. [цитировано 01.04.2020. Доступно на: https://rg.ru/2019/03/29/minzdrav-prikaz4-site-dok.html.; Kalil A.C. Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. JAMA. 2020 Mar 24. DOI:10.1001/jama.2020.4742. [Epub ahead of print].; Chen Z., Hu J., Zhang Z., et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. [cited by April 01, 2020]. Available from: https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v3. DOI:10.1101/2020.03.22.20040758.; European Medicines Agency, Guideline on good pharmacovigilance practices, Module VI - Management and reporting of adverse reactions to medicinal products. [cited by April 01, 2020]. Available from: www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilancepractices-module-vi-management-reporting-adverse-reactions_en-0.pdf , para VI.A.2.1.2.; Bauman N.L., Sandefur C. Restoring Free Speech in Medicine: How state lawmakers can overcome FDA regulations that keep doctors and payers in the dark. Goldwater Institute, at 3, June 6, 2017 [cited by April 01, 2020]. Available from: https://ssrn.com/abstract=2982168.; O’Reilly J., Dalal A. Off label or out of bounds? Prescriber and marketer liability for unapproved uses of FDA-approved drugs. Ann Health Law. 2003;12(2):295-324.; Mello M., Studdert D.M., Brennan T.A. Shifting terrain in the regulation of off-label promotion of pharmaceuticals. N Engl J Med. 2009;360(15):1557-66. DOI:10.1056/NEJMhle0807695.; Code of Federal Regulations. 21CFR312.2. Investigational new drug application [cited by April 01, 2020]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.2.; Ventola C.L. Off-label drug information: regulation, distribution, evaluation, and related controversies. P T. 2009;34(8):428-40.; Mithani Z. Informed consent for off-label use of prescription medications. Virtual Mentor. 2012;14(7):576-81. DOI:10.1001/virtualmentor.2012.14.7.oped1-1207.; Meadows W.A., Hollowell B.D. “Off-label” drug use: an FDA regulatory term, not a negative implication of its medical use. Int J Impot Res. 2008;20(2):135-44. DOI:10.1038/sj.ijir.3901619.; Fitzgerald A.S., O’Malley P.G. Staying on track when prescribing off-label. Am Fam Physician. 2014;89:4-5.; Wittich C.M., Burkle C.M., Lanier W.L. Ten common questions (and their answers) about off-label drug use. Mayo Clin Proc. 2012;87(10):982-90. DOI:10.1016/j.mayocp.2012.04.017.; Gazarian M., Kelly M., McPhee J.R., et al. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust. 2006;185(10):544-8. DOI:10.5694/j.1326-5377.2006.tb00689.; Radley D.C., Finkelstein S.N., Stafford R.S. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166(9):1021-6. DOI:10.1001/archinte.166.9.1021.; Shah S.S., Hall M., Goodman D.M., et al. Off-label Drug Use in Hospitalized Children. Arch Pediatr Adolesc Med. 2007;161(3):282-90. DOI:10.1001/archpedi.161.3.282.; Qureshi Z.P., Liu Y., Sartor O., et al. Enforcement actions involving Medicaid fraud and abuse, 1996- 2009. Arch Intern Med. 2011;171(8):785-7. DOI:10.1001/archinternmed.2011.142.; Chen H., Reeves J.H., Fincham J.E., et al. Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia Medicaid enrollees in 2001. J Clin Psychiatry. 2006;67:972- 82. DOI:10.4088/jcp.v67n0615.; Lat I., Micek S., Janzen J., et al. Off-label medication use in adult critical care patients. J Crit Care. 2011;26:89-94. DOI:10.1016/j.jcrc.2010.06.012.; Lin H.W., Phan K., Lin S.J. Trends in off-label beta-blocker use: a secondary data analysis. Clin Ther. 2006;28(10):1736-46. DOI:10.1016/j.clinthera.2006.10.015.; Loder E.W., Biondi D.M. Off-label prescribing of drugs in specialty headache practice. Headache. 2004;44:636-41. DOI:10.1111/j.1526-4610.2004.04121.x.; Picard D., Carvalho P., Bonnavia C., et al. Evaluation des prescriptions hors AMM en Dermatologie [Assessment off-label prescribing in dermatology]. Ann Dermatol Venereol. 2003;130: 507-10. DOI:AD-05-2003-130-5-0151-9638-101019-ART3.; Ratner M. Pfizer settles largest ever fraud suit for off-label promotion. Nat Biotechnol. 2009;27(11):961-2. DOI:10.1038/nbt1109-961.; Kmietowicz Z. Eli Lilly pays record $1.4bn for promoting off-label use of olanzapine. BMJ. 2009;338:b217. DOI:10.1136/bmj.b217.; Weda M., Hoebert J., Vervloet M., et al. Study on off-label use of medicinal products in the European (2019) [cited by April 01, 2020]. Available from: https://op.europa.eu/en/publication-detail/-/publication/ecf85518-d376-11e9-b4bf-01aa75ed71a110.2875/464022.; Schrier L., Hadjipanayis A., Stiris T., et al. Off-label use of medicines in neonates, infants, children, and adolescents: a joint policy statement by the European Academy of Paediatrics and the European society for Developmental Perinatal and Pediatric Pharmacology. Eur J Pediatr. 2020;179(5):839- 847. DOI:10.1007/s00431-019-03556-9.; Lenk C., Duttge G. Ethical and legal framework and regulation for off-label use: European perspective. Ther Clin Risk Manag. 2014;10:537-46. DOI:10.2147/TCRM.S40232.; Aronson J.K., Ferner R.E. Unlicensed and off-label uses of medicines: definitions and clarification of terminology. Br J Clin Pharmacol. 2017;83:2615-25. DOI:10.1111/bcp.13394.; Stafford R.S. Regulating off-label drug use: rethinking the role of the FDA. N Engl J Med. 2008;358(14):1427-9. DOI:10.1056/NEJMp0802107.; França K., Litewka S. Controversies in off-label prescriptions in dermatology: the perspective of the patient, the physician, and the pharmaceutical companies. Int J Dermatol. 2019;58:788-94. DOI:10.1111/ijd.14222.; Oliphant C.S., Owens R.E., Bolorunduro O.B., Jha S.K. Ivabradine: A Review of Labeled and Off-Label Uses. Am J Cardiovasc Drugs. 2016;16:337-47. DOI:10.1007/s40256-016-0178-z.; Schulze V., Steiner S., Hennersdorf M., Strauer B.E. Ivabradine as an alternative therapeutic trial in the therapy of inappropriate sinus tachycardia: a case report. Cardiology. 2008;110:206-8. DOI:10.1159/000111931.; Retegui G., Quintero M., Ruiz-Borrell M., Revello A. Ivabradine as a treatment option for inappropriate sinus tachycardia. Rev Esp Cardiol. 2009;62:576-88. DOI:10.1016/s1885-5857(09)71843-2.; Winum P.F., Cayla G., Rubini M., et al. A case of cardiomyopathy induced by inappropriate sinus tachycardia and cured by ivabradine. PACE. 2009;32:942-4. DOI:10.1111/j.1540-8159.2009.02414.x.; Settle A., Martino A., Lioy E., Calo L. Efficacy of ivabradine in a case of inappropriate sinus tachycardia and ventricular dysfunction. J Cardiovasc Electrophysiol. 2010;21:815-7. DOI:10.1111/j.1540-8167.2009.01699.x.; Goyal V.K., Godara S., Sadasukhi T.C., Gupta H.L. Management of inappropriate sinus tachycardia with ivabradine in a renal transplant recipient. Drug Discov Ther. 2014;8:132-3. DOI:10.5582/ddt.2014.01023.; Zellerhoff S., Hinterseer M., Felix Krull B., et al. Ivabradine in patients with inappropriate sinus tachycardia. Naunyn Schmiedebergs Arch Pharmacol. 2010;382(5-6):483-6. DOI:10.1007/s00210-010-0565-y.; Calo L., Rebecchi M., Sette A., et al. Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia. Heart Rhythm. 2010;7:1318-23. DOI:10.1016/j.hrthm.2010.05.034.; Benezet-Mazuecos J., Rubio J.M., Farre J., et al. Long-term outcomes of ivabradine in inappropriate sinus tachycardia patients: appropriate efficacy or inappropriate patients. PACE. 2013;36:830-6. DOI:10.1111/pace.12118.; Ptaszynski P., Kaczmarek K., Ruta J., et al. Ivabradine in the treatment of inappropriate sinus tachycardia in patients after successful radiofrequency catheter ablation of atrioventricular node slow pathway. PACE. 2013;36:42-9. DOI:10.1111/pace.12018; Boeken U., Assmann A., Mehdiani A., et al. Ivabradine in patients with inappropriate sinus tachycardia after cardiac surgery: alternative to b-blockers? Thorac Cardiovasc Surg. 2012;60:119. DOI:10.1055/s-0031-1297766.; Cappato R., Castelvecchio S., Ricci C., et al. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation. J Am Coll Cardiol. 2012;60:1323-9.DOI:10.1016/j.jacc.2012.06.031.; Ptaszynski P., Kaczmarek K., Ruta J., et al. Metoprolol succinate vs. ivabradine in the treatment of inappropriate sinus tachycardia in patients unresponsive to previous pharmacological therapy. Europace. 2013;15:116—121. DOI:10.1093/europace/eus204.; Ptaszynski P., Kaczmarek K., Ruta J., et al. Ivabradine in combination with metoprolol succinate in the treatment of inappropriate sinus tachycardia. J Cardiovasc Pharmacol Ther. 2013;18:338-44. DOI:10.1177/1074248413478172.; Sheldon R.S., Grubb B.P. II, Olshansky B., et al. 2015 Heart Rhythm Society Expert Consensus Statement on the Diagnosis and Treatment of Postural Tachycardia Syndrome, Inappropriate Sinus Tachycardia, and Vasovagal Syncope. Heart Rhythm. 2015;12:e41-63. DOI:10.1016/j.hrthm.2015.03.029.; Frattarelli D.A., Galinkin J.L., Green T.P., et al. American Academy of Pediatrics Committee on Drugs. Off-label use of drugs in children. Pediatrics. 2014;133:563-7. DOI:10.1542/peds.2013-4060.; Connolly H.M., Crary J.L., McGoon M.D., et al. Valvular heart disease associated with fenfluraminephentermine. N Engl J Med. 1997;337:581-8. DOI:10.1056/NEJM199708283370901.; Friedman M.A., Woodcock J., Lumpkin M.M., et al. The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA. 1999;281:1728-34. DOI:10.1001/jama.281.18.1728.; Cheng W.H., Chao T.F., Lin Y.J., et al. Low-Dose Rivaroxaban and Risks of Adverse Events in Patients With Atrial Fibrillation. Stroke. 2019;50:2574-7. DOI:10.1161/STROKEAHA.119.025623.; Paciaroni M., Agnelli G., Caso V., et al. Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. Stroke. 2019;50(8):2168-74. DOI:10.1161/STROKEAHA.119.025350.; Santos J., António N., Rocha M., Fortuna A. Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: A systematic review. Br J Clin Pharmacol. 2019 Oct 20. DOI:10.1111/bcp.14127. [Epub ahead of print].; Noel N., Dutasta F., Costedoat-Chalumeau N., et al. Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. Autoimmun Rev. 2015;14(8):680-5. DOI:10.1016/j.autrev.2015.03.007.; Cohen H., Hunt B.J., Efthymiou M., et al.; RAPS trial investigators. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol 2016;3(9):e426-436. DOI:10.1016/S2352-3026(16)30079-5.; Ordi-Ros J., Sáez-Comet L., Pérez-Conesa M., et al. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial. Ann Intern Med 2019 Oct 15. DOI:10.7326/M19-0291. [Epub ahead of print].; Konstantinides S.V., Meyer G., Becattini C., et al.; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543-603. DOI:10.1093/eurheartj/ehz405.; Pokorney S.D. American College of Cardiology Webpage, AHA 2019 Presentation Slides for the RENAL-AF Trial [cited by April 01, 2020]. Available from: https://www.acc.org/education-andmeetings/image-and-slide-gallery/media-detail?id=469e5bd88-f4d2bb8ec183e71521637.; Reinecke H., Jurgensmeyer S., Engelbertz C., et al. Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: The AXADIA-AFNET 8 study. BMJ Open. 2018;8(9):e022690. DOI:10.1136/bmjopen-2018-022690.; Noseworthy P.A., Kaufman E.S., Chen L.Y., et al. Subclinical and Device-Detected Atrial Fibrillation: Pondering the Knowledge Gap: A Scientific Statement From the American Heart Association. Circulation. 2019;140(25):e944-e963. DOI:10.1161/CIR.0000000000000740.; Lopes R.D., Alings M., Connolly S.J., et al. Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. Am Heart J. 2017;189:137-45. DOI:10.1016/j.ahj.2017.04.008.; Kirchhof P., Blank B.F., Calvert M., et al. Probing oral anticoagulation in patients with atrial high rate episodes: rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. Am Heart J. 2017;190:12-8. DOI:10.1016/j.ahj.2017.04.015.; Hart R.G., Sharma M., Mundl H., et al. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. N Engl J Med. 2018;378(23):2191-201. DOI:10.1056/NEJMoa1802686.; Diener H.C., Sacco R.L., Easton J.D., et al. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. N Engl J Med. 2019;380(20):1906-17. DOI:10.1056/NEJMoa1813959.; Busko M. Rivaroxaban May Reduce Stroke After ESUS With Large Left Atrium [cited by April 01, 2020]. Available from: https://www.medscape.com/viewarticle/904151.; Kamel H., Longstreth W.T. Jr, Tirschwell D.L., et al. The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: Rationale and methods. Int J Stroke. 2019;14(2):207-14. DOI:10.1177/1747493018799981.; Ay C., Pabinger I., Cohen A.T. Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thromb Haemost. 2017;117:219-30. DOI:10.1160/TH16-08-0615.; Lyman G.H., Bohlke K., Falanga A., American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract. 2015;11:e442-e444. DOI:10.1200/JOP.2015.004473.; Kearon C., Akl E.A., Ornelas J., et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315-52. DOI:10.1016/j.chest.2015.11.026.; Lee A.Y., Levine M.N., Baker R.I., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146- 53. DOI:10.1056/NEJMoa025313.; Lee A.Y.Y., Kamphuisen P.W., Meyer G., Bauersachs R., et al.; CATCH Investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015;314:677-86. DOI:10.1001/jama.2015.9243.; Raskob G.E., van Es N., Verhamme P., et al.; Hokusai VTE Cancer Investigators. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018;378:615-24. DOI:10.1056/NEJMoa1711948.; Agnelli G., Becattini C., Meyer G., et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med. 2020 Mar 29. DOI:10.1056/NEJMoa1915103. [Epub ahead of print].; https://www.rpcardio.com/jour/article/view/2181

Availability: https://www.rpcardio.com/jour/article/view/2181
https://doi.org/10.20996/1819-6446-2020-04-14

Antithrombotic therapy in patients with coronary heart disease and atrial fibrillation after direct myocardial revascularization ; Антитромботическая терапия у пациентов с ишемической болезнью сердца и фибрилляцией предсердий после прямой реваскуляризации миокарда

Authors: M. A. Kirgizova, O. R. Eshmatov, Yu. I. Bogdanov, R. E. Batalov, S. V. Popov, М. А. Киргизова, О. Р. Эшматов, Ю. И. Богданов, Р. Е. Баталов, С. В. Попов

Source: Siberian Journal of Clinical and Experimental Medicine; Том 35, № 4 (2020); 49-56 ; Сибирский журнал клинической и экспериментальной медицины; Том 35, № 4 (2020); 49-56 ; 2713-265X ; 2713-2927

Subject Terms: дабигатран, atrial fibrillation, ischemic heart disease, direct oral anticoagulants, фибрилляция предсердий, ишемическая болезнь сердца, прямые пероральные антикоагулянты, ривароксабан, апиксабан

File Description: application/pdf

Relation: https://www.sibjcem.ru/jour/article/view/1073/576; Haim M., Hoshen M., Reges O., Rabi Y., Balicer R., Leibowitz M. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non valvular atrial fibrillation. J. Am. Heart Assoc. 2015;4(1):e001486. DOI:10.1161/JAHA.114.001486.; Lippi G., Sanchis-Gomar F., Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int. J. Stroke. 2020;1747493019897870. DOI:10.1177/1747493019897870.; Valgimigli M., Bueno H., Byrne R., Collet J.-P., Costa F., Jeppsson A. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association of Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2018;39(3):213–260. DOI:10.1093/eurheartj/ehx419.; Бокерия Л.А., Аронов Д.М., Барбараш О.Л., Бубнова М.Г., Князева Т.А., Лямина Н.П. и др. Российские клинические рекомендации. Коронарное шунтирование больных ишемической болезнью сердца: реабилитация и вторичная профилактика. CardioСоматика. 2016;7(3–4):5–71.; Vohra H.A., Whistance R., Modi A., Ohri S.K. The inflammatory response to miniaturised extracorporeal circulation: a review of the literature. Mediators of Inflammation. 2009;707042. DOI:10.1155/2009/707042.; Zheng A.S.Y., Churilov L., Colley R.E., Goh C., Davis S.M., Yan B. Association of aspirin resistance with increased stroke severity and infarct size. JAMA Neurol. 2013;70(2):208–213. DOI:10.1001/jamaneurol.2013.601.; Мартынов А.И., Акатова Е.В., Урлаева И.В., Николин О.П. Истинная резистентность и псевдорезистентность к аспирину. Рациональная Фармакотерапия в Кардиологии. 2013;9(4):301–305. DOI:10.20996/1819-6446-2013-9-3-301-305.; Wang Y., Chen S., Shi J.W., Dong W.-G. Benefit and Safety of Dual Antiplatelet Therapy after Coronary Artery Bypass Grafting for Off-pump CABG: A Systematic Review and Meta-analysis. British Journal of Medicine and Medical Research. 2015:9(11):1–15. DOI:10.9734/BJMMR/2015/19433.; Aryana A., Singh S.K., Singh S.M., O’Neill P.G., Bowers M.R., Allen S.L. et al. Association between incomplete surgical ligation of left atrial appendage and stroke and systemic embolization. Heart Rhythm. 2015;12(7):1431–1437. DOI:10.1016/j.hrthm.2015.03.028.; Chatterjee S., Alexander J.C., Pearson P.J., Feldman T. Left atrial appendage occlusion: Lessons learned from surgical and transcatheter experiences. Ann. Thorac. Surg. 2011;92(6):2283–2292. DOI:10.1016/j.athoracsur.2011.08.044.; Budera P., Straka Z., Osmančík P., Vaněk T., Jelínek S., Hlavička J. et al. Comparison of cardiac surgery with left atrial surgical ablation vs. cardiac surgery without atrial ablation in patients with coronary and/or valvular heart disease plus atrial fibrillation: final results of the PRAGUE-12 randomized multicentre study. Eur. Heart J. 2012;33(21):2644–2652. DOI:10.1093/eurheartj/ehs290.; Двойная антитромбоцитарная терапия при ишемической болезни сердца: обновленная версия 2017 года. Российский кардиологический журнал. 2018;23(8):113–163. DOI:10.15829/1560-4071-2018-8-113-163.; Сулимов В.А., Голицын С.П., Панченко Е.П., Попов С.В., Ревишвили А.Ш., Шубик Ю.В. и др. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ. Российский кардиологический журнал. 2013;4(102):1–100.; Сулимов В.А., Напалков Д.А., Соколова А.А. Сравнительная эффективность и безопасность новых пероральных антикоагулянтов. Рациональная Фармакотерапия в Кардиологии. 2013;9(4):433–438.; Tabl M.A. Безопасность и эффективность комбинации ривароксабана и клопидогрела для лечения фибрилляции предсердий у пациентов с острым коронарным синдромом. Международный журнал сердца и сосудистых заболеваний. 2017;5(16):22–30.; Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomström-Lundqvist C. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): The task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J. 2020;ehaa612. DOI:10.1093/eurheartj/ehaa612.; https://www.sibjcem.ru/jour/article/view/1073

Availability: https://www.sibjcem.ru/jour/article/view/1073
https://doi.org/10.29001/2073-8552-2020-35-4-49-56

The role of edoxaban in preventing thromboembolic complications in patients with atrial fibrillation ; Роль эдоксабана в профилактике тромбоэмболических осложнений у пациентов с фибрилляцией предсердий

Authors: O. O. Shakhmatova, О. О. Шахматова

Source: Aterotromboz = Atherothrombosis; № 2 (2020); 28-43 ; Атеротромбоз; № 2 (2020); 28-43 ; 2658-5952 ; 2307-1109 ; 10.21518/2307-1109-2020-2

Subject Terms: инсульт, direct oral anticoagulants, atrial fibrillation, cardioversion, catheter ablation, bleeding, stroke, прямые пероральные антикоагулянты, фибрилляция предсердий, кардиоверсия, катетерная абляция, кровотечения

File Description: application/pdf

Relation: https://www.aterotromboz.ru/jour/article/view/225/250; Camm A.J., Bounameaux H. Edoxaban: a new oral direct factor xa inhibitor. Drugs. 2011;71(12):1503-1526. doi:10.2165/11595540-000000000-00000.; Ogata K., Mendell-Harary J., Tachibana M., Masumoto H., Oguma T., Kojima M., Kunitada S. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50(7):743-753. doi:10.1177/0091270009351883.; Lip G.Y., Agnelli G. Edoxaban: a focused review of its clinical pharmacology. Eur Heart J. 2014;35(28):1844-1855. doi:10.1093/eurheartj/ehu181.; Duchin K., Duggal A., Atiee G.J., Kidokoro M., Takatani T., Shipitofsky N.L. et al. An open-label crossover study of the pharmacokinetics of the 60-mg edoxaban tablet crushed and administered either by a nasogastric tube or in apple puree in healthy adults. Clin Pharmacokinet. 2018;57(2):221-228. doi:10.1007/s40262-017-0554-0.; Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomstrom-Lundqvist C. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2020;ehaa612. doi:10.1093/eur-heartj/ehaa612.; Parasrampuria D.A., Truitt K.E. Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa. Clin Pharmacokinet. 2016;55(6):641-655. doi:10.1007/s40262-015-0342-7.; Corsini A., Ferri N., Proietti M., Boriani G. Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice. Drugs. 2020;80(11):1065-1083. doi:10.1007/s40265-020-01328-6.; Matsushima N., Lee F., Sato T., Weiss D., Mendell J. Bioavailability and safety of the factor Xa inhibitor edoxaban and the efects of quinidine in healthy subjects. Clin Pharmacol Drug Dev. 2013;2(4):358-366. doi:10.1002/cpdd.53.; Parasrampuria D.A., Mendell J., Shi M., Matsushima N., Zahir H., Truitt K. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine. Br J Clin Pharmacol. 2016;82(6):1591-1600. doi:10.1111/bcp.13092.; Andreini D., Arbelo E., Barbato E., Bartorelli A.L., Baumbach A., Behr E.R. et al. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. Available at: https://escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance.; Ruff C.T., Giugliano R.P., Braunwald E., Morrow D.A., Murphy S.A., Kuder J.F. et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015;385(9984):2288-2295. doi:10.1016/S0140-6736(14)61943-7.; Giugliano R.P., Ruff C.T., Braunwald E., Murphy S.A., Wiviott S.D., Halperin J.L. et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-2104. doi:10.1056/NEJMoa1310907.; Weitz J.I., Connolly S.J., Patel I., Salazar D., Rohatagi S., Mendell J. et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104(3):633-641. doi:10.1160/TH10-01-0066.; Pokorney S.D., Simon D.N., Thomas L., Fonarow G.C., Kowey P.R., Chang P. et al. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. Am Heart J. 2015;170(1):141-148. doi:10.1016/j.ahj.2015.03.017.; Rost N.S., Giugliano R.P., Ruff C.T., Murphy S., Crompton A., Mercuri M. et al. Efficacy and safety of edoxaban vs. warfarin in high-risk patients: the ENGAGE AF-TIMI 48 trial. Int J Stroke. 2014;9(3):38-39. Available at: https://www.researchgate.net/publication/279028563_Efficacy_and_safety_of_edoxaban_vs_warfarin_in_high-risk_patients_The_ENGAGE_AF-TIMI_48_trial.; Giugliano R.P., Ruff C.T., Rost N.S., Silverman S., Wiviott S.D., Lowe C. et al. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48. Stroke. 2014;45(8):2372-2378. doi:10.1161/STROKEAHA.114.006025.; Kato E.T., Giugliano R.P., Ruff C.T., Koretsune Y., Yamashita T., Kiss R.G. et al. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc. 2016;5(5):e003432. doi:10.1161/JAHA.116.003432.; Steffel J., Giugliano R.P., Braunwald E., Murphy S.A., Mercuri M., Choi Y. et al. Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis. J Am Coll Cardiol. 2016;68(11):1169-1178. doi:10.1016/j.jacc.2016.06.034.; Magnani G., Giugliano R.P., Ruff C.T., Murphy S.A., Nordio F., Metra M. et al. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48. Eur J Heart Fail. 2016;18(9):1153-1161. doi:10.1002/ejhf.595.; Bohula E.A., Giugliano R.P., Ruff C.T., Kuder J.F., Murphy S.A., Antman E.M., Braunwald E. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation. 2016;134(1):24-36. doi:10.1161/CIRCULATIONAHA.116.022361.; Nielsen P.B., Lane D.A., Rasmussen L.H., Lip G.Y., Larsen T.B. Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. Clin Res Cardiol. 2015;104(5):418-429. doi:10.1007/s00392-014-0797-9.; Carnicelli A.P., De Caterina R., Halperin J.L., Renda G., Ruff C.T., Trevisan M. et al. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. Circulation. 2017;135(13):1273-1275. doi:10.1161/CIRCULATIONAHA.116.026714.; Capodanno D., Huber K., Mehran R., Lip G.Y.H., Faxon D.P., Granger C.B. et al. Management of antithrombotic therapy in atrial fibrillation patients undergoing PCI: JACC state-of-the-art review. J Am Coll Cardiol. 2019;74(1):83-99. doi:10.1016/j.jacc.2019.05.016.; Cannon C.P., Bhatt D.L., Oldgren J., Lip G.Y.H., Ellis S.G., Kimura T. et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(16):1513-1524. doi:10.1056/NEJMoa1708454.; Gibson C.M., Mehran R., Bode C., Halperin J., Verheugt F.W., Wildgoose P. et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423-2434. doi:10.1056/NEJMoa1611594.; Lopes R.D., Heizer G., Aronson R., Vora A.N., Massaro T., Mehran R. et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380(16):1509-1524. doi:10.1056/NEJMoa1817083.; Vranckx P., Valgimigli M., Eckardt L., Tijssen J., Lewalter T., Gargiulo G. et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394(10206):1335-1343. doi:10.1016/S0140-6736(19)31872-0.; Goette A., Merino J.L., Ezekowitz M.D., Zamoryakhin D., Melino M., Jin J. et al. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet. 2016;388(10055):1995-2003. doi:10.1016/S0140-6736(16)31474-X.; Hohnloser S.H., Camm J., Cappato R., Diener H.C., HeidbQcheL H., Mont L. et al. Uninterrupted edoxa-ban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. Eur Heart J. 2019;40(36):3013-3021. doi:10.1093/eurheartj/ehz190.; Calkins H., Willems S., Gerstenfeld E.P., Verma A., Schilling R., Hohnloser S.H. et al. Uninterrupted dabig-atran versus warfarin for ablation in atrial fibrillation. N Engl J Med. 2017;376(17):1627-1636. doi:10.1056/NEJMoa1701005.; Kirchhof P., Haeusler K.G., Blank B., De Bono J., Callans D., Elvan A. et al. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. Eur Heart J. 2018;39(32):2942-2955. doi:10.1093/eurheartj/ehy176.; Lee S.R., Choi E.K., Han K.D., Jung J.H., Oh S., Lip G.Y.H. Edoxaban in Asian Patients With Atrial Fibrillation: Effectiveness and Safety. J Am Coll Cardiol. 2018;72(8):838-853. doi:10.1016/j.jacc.2018.05.066.; de Groot J.R., Weiss T.W., Kelly P., Monteiro P., Deharo J.C., de Asmundis C. et al. Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: One year follow up of the prospective observational ETNA-AF-Europe study. Eur Heart J Cardiovasc Pharmacother. 2020;pvaa079. doi:10.1093/ehjcvp/pvaa079.; Connolly S.J., Crowther M., Eikelboom J.W., Gibson C.M., Curnutte J.T., Lawrence J.H. et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. 2019;380(14):1326-1335. doi:10.1056/NEJMoa1814051.; Bae J.P., Dobesh P.P., Klepser D.G., Anderson J.D., Zagar A.J., McCollam P.L., Tomlin M.E. Adherence and dosing frequency of common medications for cardiovascular patients. Am J Manag Care. 2012;18(3):139-146. Available at: https://pubmed.ncbi.nlm.nih.gov/22435907/; Laliberte F., Nelson W.W., Lefebvre P., Schein J.R., Rondeau-Leclaire J., Duh M.S. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther. 2012;29(8):675-690. doi:10.1007/s12325-012-0040-x.; Alberts M.J., Peacock W.F., Fields L.E., Bunz T.J., Nguyen E., Milentijevic D. et al. Association between once- and twice-daily direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic stroke. Int J Cardiol. 2016;215:11-13. doi:10.1016/j.ijcard.2016.03.212.; Renda G., De Caterina R. The new oral anticoagulants in atrial fibrillation: once daily or twice daily? Vascul Pharmacol. 2013;59(3-4):53-62. doi:10.1016/j.vph.2013.07.003.; https://www.aterotromboz.ru/jour/article/view/225

Availability: https://www.aterotromboz.ru/jour/article/view/225
https://doi.org/10.21518/2307-1109-2020-2-28-43

Apixaban role in the treatment of venous thromboembolic complications in patients with active cancer ; Роль апиксабана в лечении венозных тромбоэмболических осложнений у больных с активным раком

Authors: E. P. Panchenko, Е. П. Панченко

Contributors: This article was published with the support of Pfizer. The article may show the author's position, which may differ from the Pfizer's position, Статья опубликована при поддержке компании «Пфайзер». В статье может быть выражена позиция автора, которая может отличаться от позиции компании «Пфайзер»

Source: Aterotromboz = Atherothrombosis; № 1 (2020); 47-54 ; Атеротромбоз; № 1 (2020); 47-54 ; 2658-5952 ; 2307-1109 ; 10.21518/2307-1109-2017-3

Subject Terms: апиксабан, lower-extremity deep vein thrombosis, pulmonary embolism, direct oral anticoagulants, dalteparin, apixaban, тромбоз глубоких вен нижних конечностей, тромбоэмболия легочной артерии, прямые пероральные антикоагулянты, дальтепарин

File Description: application/pdf

Relation: https://www.aterotromboz.ru/jour/article/view/213/247; Heit J.A., O'FaLLon W.M., Petterson T.M., Lohse C.M., Silverstein M.D., Mohr D.N. Relative Impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002;162(11):1245-1248. doi:10.1001/archinte.162.11.1245.; Khorana A., DaLaL M., Lin J., ConnoLLy G.C. Incidence and predictors of venous thromboemboLism (VTE) among ambuLatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013;119(3):648-555. doi:10.1002/cncr.27772.; Lee A.Y., Kamphuisen P.W., Meyer G., Bauersachs R., Janas M.S., Jarner M.F., Khorana A.A. Tinzaparin vs warfarin for treatment of acute venous thromboemboLism in patients with active cancer: a randomized cLinicaL triaL. JAMA. 2015;314(7):677-686. doi:10.1001/jama.2015.9243.; Deitcher S.R., KessLer C.M., MerLi G., Rigas J.R., Lyons R.M., Fareed J. Secondary prevention of venous thromboemboLic events in patients with active cancer: enoxaparin aLone versus initial enoxa-parin foLLowed by warfarin for a 180-day period. Clin Appl Thromb Hemost. 2006;12(4):389-396. doi:10.1177/1076029606293692.; Lee A.Y., Levine M.N., Baker R.I., Bowden C., Kakkar A.K., Prins M. et aL. Low-moLecuLar-weight heparin versus a coumarin for the prevention of recurrent venous thromboemboLism in patients with cancer. N Engl J Med. 2003;349:146-153. doi:10.1056/NEJMoa025313.; Meyer G., Marjanovic Z., VaLcke J., Lorcerie B., GrueL Y., SoLaL-CeLigny P. et aL. Comparison ofLow-moLecuLarweight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162(15):1729-1735. doi:10.1001/archinte.162.15.1729.; Hull R.D., Pineo G.F., Brant R.F., Mah A.F., Burke N., Dear R. et al. Long-termlow-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006;119(12):1062-1072. doi:10.1016/j.amjmed.2006.02.022.; Posch F., Konigsbrugge O., Zielinski C., Pabinger I., Ay C. Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res. 2015;136(3):582-589. doi:10.1016/j.thromres.2015.07.011.; Khorana A., Yannicelli D., McCrae K.R., Milentijevic D., Crivera C., Nelson W.W., Schein J.R. Evaluation of US prescription patterns: are treatment guidelines for cancer-associated venous thromboembolism being followed? Thromb Res. 2016;145:51-53. doi:10.1016/j.thromres.2016.07.013.; Schulman S., Kearon C., Kakkar A.K., Mismetti P., Schellong S., Eriksson H. et al. RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(2):2342-2352. doi:10.1056/NEJMoa0906598.; EINSTEIN Investigators, Bauersachs R., Berkowitz S.D., Brenner B., Decousus H., Gallus A.S., Lensing A.W. et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-2510. doi:10.1056/NEJMoa1007903.; EINSTEIN-PE Investigators, Buller H.R., Prins M.H., Lensin A.W., Decousus H., Jacobson B.F., Minar E. et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-1297. doi:10.1056/NEJMoa1113572.; Prins M.H., Lensing W.A.A., Bauersachs R., van Bellen B., Bounameaux H., Brighton T.A. et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013;11(1):21. doi:10.1186/1477-9560-11-21.; Agnelli G., Buller H.R., Cohen A., Curto M., Gallus A.S., Jonson M. et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808. doi:10.1056/NEJMoa1302507.; Hokusai-VTE Investigators, Buller H.R., Decousus H., Grosso M.A. et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406-1415. doi:10.1056/NEJMoa1306638.; Raskob G.E., van E.N., Verhamme P., Carrier M., Di Nisio M., Garcia D. et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615-624. doi:10.1056/NEJMoa1711948.; Young A.M., Marshall A., Thirlwall J., Chapman O., Lokare A., Hill C. et al. Comparison of an oral factor Xa inhibitor withlow molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36(20):2017-2023. doi:10.1200/JCO.2018.78.8034.; McBane R., Wysokinski W. E., Le-Rademacher J.G., Zemla T., Ashrani A., Tafur A. et al. Apixaban and Dalteparin in Active Malignancy-Associated Venous Thromboembolism: The ADAM VTE Trial. J Thromb Haemost. 2020;18(2):411-421. doi:10.1111/jth.14662.; Konstantinides S.V., Meyer G., Becattini C., Bueno H., Geersing G.-J., Harjola V.-P. et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmo-naryembolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543-603. doi:10.1093/eurheartj/ehz405.; Agnelli G., Becattini C., Meyer G., Murioz A., Huisman M.V., Connors J.M. et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Eng J Med. 2020. doi:10.1056/NEJMoa1915103.; Khorana A.A., Francis C.W., Culakova E., Kuderer N.M., Lyman G.H. Thromboembolism is aleading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632- 634. doi:10.1111/j.1538-7836.2007.02374.x.; https://www.aterotromboz.ru/jour/article/view/213

Availability: https://www.aterotromboz.ru/jour/article/view/213
https://doi.org/10.21518/2307-1109-2020-1-47-54

PROPHYLAXIS OF VENOUS THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ACTIVE ONCOLOGICAL DISEASE, RECEIVING MEDICAL ANTI-CANCER CHEMOTHERAPY IN OUTPATIENT CONDITIONS. ROLE OF APIXABAN ; ПРОФИЛАКТИКА ВЕНОЗНЫХ ТРОМБОЭМБОЛИЧЕСКИХ ОСЛОЖНЕНИЙ У ПАЦИЕНТОВ С АКТИВНЫМ ОНКОЛОГИЧЕСКИМ ЗАБОЛЕВАНИЕМ, ПОЛУЧАЮЩИХ МЕДИКАМЕНТОЗНУЮ ПРОТИВОРАКОВУЮ ХИМИОТЕРАПИЮ В АМБУЛАТОРНЫХ УСЛОВИЯХ. РОЛЬ АПИКСАБАНА

Authors: Yu. A. Fedotkina, E. P. Panchenko, Ю. А. Федоткина, Е. П. Панченко

Source: Aterotromboz = Atherothrombosis; № 2 (2019); 46-54 ; Атеротромбоз; № 2 (2019); 46-54 ; 2658-5952 ; 2307-1109 ; 10.21518/2307-1109-2019-2

Subject Terms: апиксабан, low-molecular weight heparins, direct oral anticoagulants, apixaban, медикаментозная профилактика венозных тромбозов у онкологических пациентов, получающих химиотерапию, низкомолекулярные гепарины, прямые пероральные антикоагулянты

File Description: application/pdf

Relation: https://www.aterotromboz.ru/jour/article/view/198/227; Levitan N., Dowlati A., Remick S.C., et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999;(78):285–91. doi:10.1097/00005792-199909000-00001 .; Chew H.K., Wun T., Harvey D., et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;(166):458–64. doi:10.1001/archinte.166.4.458.; Khorana A.A., Francis C.W., Culakova E., et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;(5):632–34. doi:10.1111/j.1538-7836.2007.02374.x.; Heit J.A., Spencer F.A., White R.H. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;(41):3–14. doi:10.1007/s11239-015-1311-6.; Timp J.F., Braekkan S.K., Versteeg H.H., et al. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;(122):1712–1723. doi:10.1182/blood-2013-04-460121.; Ahlbrecht J., Dickmann B., Ay C., et al. Tumor grade is associated with venous thromboembolism in patients with cancer: results from the vienna cancer and thrombosis study. J Clin Oncol. 2012;(30):3870–3875. doi:10.1200/jco.2011.40.1810.; Trinh V.Q., Karakiewicz P.I., Sammon J., et al. Venous thromboembolism after major cancer surgery: temporal trends and patterns of care. JAMA Surg. 2014;(149):43–49. doi:10.1001/jamasurg.2013.3172 .; Raskob G.E., van Es N., Verhamme P., et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;(378):615–624. doi:10.1056/nejme1800041.; Young A.M., Marshall A., Thirlwall J., et al. Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;(36):2017–2023. doi:10.1200/jco.2018.78.8034.; McBane R., Wysokinski W., Le-Rademacher J., et al. Apixaban, dalteparin, in active cancer associated venous thromboembolism, the ADAM VTE trial. Blood. 2018;(132):421. doi:10.1182/blood-2018-99-118808.; Khorana A.A., Soff G.A., Kakkar A.K., et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 2019;(380):720–728. doi:10.1056/nejmoa1814630.; Carrier M., Abou-Nassar K., Mallick R., et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 2019;(380):711–719. doi:10.1056/nejmoa1814468.; Short N.J., Connors J.M. New oral anticoagulants and the cancer patient. Oncologist.2014;(19):82–93. doi:10.1634/theoncologist.2013-0239.; Bellesoeur A., Thomas-Schoemann A., Allard M., et al. Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: clinical consequences. Crit Rev Oncol Hematol. 2018;(129):102–112. doi:10.1016/j.critrevonc.2018.06.015.; Федоткина Ю.А. Профилактика венозных тромбоэмболических осложнений у онкологических больных. Атеротромбоз. 2019;(1):8-24. doi:10.21518/2307-1109-2019-1-8-24.; Ay C., Pabinger I., Cohen A.T. Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thromb Haemost. 2017;(117):219–230. doi:10.1160/th16-08-0615.; Verso M., Agnelli G., Barni S., et al. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 2012;(7):291–292. doi:10.1007/s11739-012-0784-y.; Pelzer U., Sinn M., Stieler J., et al. Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy? Dtsch Med Wochenschr 2013;(138):2084–2088. doi:10.1055/s-0033-1349608.; van Es N., Di Nisio M., Cesarman G., et al. Comparison of risk prediction scores for venous thromboembolism in cancer patients:a prospective cohort study. Haematologica. 2017;(102):1494–501. doi:10.3324/haematol.2017.169060.; Mansfield A.S., Tafur A.J., Wang C.E., et al. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer. J Thromb Haemost. 2016;(14):1773–1778. doi:10.1111/jth.13592.; Bezan A., Posch F., Ploner F., et al. Risk stratification for venous thromboembolism in patients with testicular germ cell tumors. PLoS One. 2017;(12):e0176283. doi:10.1371/journal.pone.0176283.; Gerotziafas G.T., Taher A., Abdel-Razeq H., et al. A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS- cancer-associated thrombosis study. Oncologist. 2017;(22):1222–1231. doi:10.1634/theoncologist.2016-0414.; Cella C.A., Di Minno G., Carlomagno C., et al. Preventing venous thromboembolism in ambulatory cancer patients: the ONKOTEV study. Oncologist. 2017;(22):601–608. doi:10.1634/theoncologist.2016-0246.; Farge D., Debourdeau P., Beckers M., Baglin C., Bauersachs R.M., Brenner B., et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost. 2013;(11):56–70. doi:10.1111/jth.12070.; Farge D., Khorana Al. et al. 2019 International clinical practice guidelines for the the treatment and prophylaxis VTE in patients with cancer. Lancet Oncol. 2019;20(10):e566-e581. doi:10.1016/S1470-2045(19)30336-5.; Agnelli G., Gussoni G., Bianchini C., Verso M., et al Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;(10):943–949. doi:10.1016/s1470-2045(09)70232-3.; Agnelli G., George D.J., Kakkar A.K., et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;(366):601–6092. doi:10.1056/nejmoa1108898.; Alok A. Khorana, Charles W. Francis, Nicole M. Kuderer et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. Thromb Res. 2017;151:89-95. doi:10.1016/j.thromres.2017.01.009.; Levine M.N., Gu C., Liebman H.A., et al A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost. 2012;10(5):807-814. doi:10.1111/j.1538-7836.2012.04693.x.; Sohne M., Kruip M.J.H.A., Nijkeuter M., Tick L., Kwakkel H., Halkes S.J.M., et al. Accuracy of clinical decision rule, D-dimer and spiral computed tomography in patients with malignancy, previous venous thromboembolism, COPD or heart failure and in older patients with suspected pulmonary embolism. J Thromb Haemost. 2006; (4):1042–1046. doi:10.1111/j.1538-7836.2006.01918.x.; Knowlson L., Bacchu S., Paneesha S., McManus A., Randall K., Rose P., et al. Elevated D-dimers are also a marker of underlying malignancy and increased mortality in the absence of venous thromboembolism. J Clin Pathol. 2010;(63):818–822. doi:10.1136/jcp.2010.076349.; Falanga A., Roila F. On behalf of the ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guideline. Annals of Oncology. 2011;22(suppl_6):vi85–vi92. doi:10.1093/annonc/mdr392.; Howard L.S., Hughes R.J. NICE guideline: management of venous thromboembolic diseases and role of thrombophilia testing. Thorax. 2013;68:391-393. doi:10.1136/thoraxjnl-2012-202376.; Kearon C., Akl E.A., Comerota A.J., Prandoni P., Bounameaux H., Goldhaber S.Z. et al. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians. Evidence-Based Clinical Practice Guidelines. Chest. 2012;141 e419S-94S https://doi.org/10.1378/chest.11-2301; Carrier M., Nassar K.A., Mallick R. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med. 2019;(380):711-719. doi:10.1056/NEJMoa1814468.; Farge D., Bounameaux H., Khorana A., et al International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients wth cancer. Lancet Oncol. 2016;(17):e452-466. doi:10.1016/s1470-2045(16)30369-2.; Blom J.АU., et al. Malignancies, Prothrombotic Mutations, and the Risk of Venous Thrombosis. JAMA, 2005;293(6):715. doi:10.1001/jama.293.6.715; Carney B.J., Uhlmann E.J., Puligandla M., et al. Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors. J Throm Haemost. 2019;17(01):72–76. doi:10.1111/jth.14336.; Miranda S., Benhamou Y., Wells Ph., Carrier M. Safety of Primary Thromboprophylaxis Using Apixaban in Ambulatory Cancer Patients with Intracranial Metastatic Disease or Primary Brain Tumors. Thromb Haemost. 2019;119(11):1886-1887. doi:10.1055/s-0039-1695769.; Khorana A.A., Connolly G.C. Assessing risk of venous thromboembolism in the patient with cancer. Clin Oncol. 2009;(27):4839-4847. doi:10.1200/JCO.2009.22.3271.; https://www.aterotromboz.ru/jour/article/view/198

Availability: https://www.aterotromboz.ru/jour/article/view/198
https://doi.org/10.21518/2307-1109-2019-2-46-54

APPROACHES TO THE CHOICE OF ANTICOAGULANT THERAPY IN THE TREATMENT OF PATIENTS WITH COMBINATION OF ATRIAL FIBRILLATION WITH CORONARY HEART DISEASE OR PERIPHERAL ATHEROSCLEROSIS: POTENTIAL OF APIXABAN ; ПОДХОДЫ К ВЫБОРУ АНТИКОАГУЛЯНТНОЙ ТЕРАПИИ В ЛЕЧЕНИИ БОЛЬНОГО С СОЧЕТАНИЕМ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ, ИШЕМИЧЕСКОЙ БОЛЕЗНИ СЕРДЦА И ПЕРИФЕРИЧЕСКОГО АТЕРОСКЛЕРОЗА: ВОЗМОЖНОСТИ АПИКСАБАНА

Authors: O. Ostroumova D., A. Kochetkov I., I. Orlova Yu., E. Smolyarchuk A., J. Pavlova S., О. Остроумова Д., А. Кочетков И., И. Орлова Ю., Е. Смолярчук А., Ю. Павлова С.

Source: Rational Pharmacotherapy in Cardiology; Vol 14, No 3 (2018); 441-450 ; Рациональная Фармакотерапия в Кардиологии; Vol 14, No 3 (2018); 441-450 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2018-14-3

Subject Terms: atrial fibrillation, coronary artery disease, peripheral artery disease, direct oral anticoagulant, apixaban, фибрилляция предсердий, ишемическая болезнь сердца, заболевание периферических артерий, прямые пероральные антикоагулянты, апиксабан

File Description: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/1701/1675; Stewart S., Hart C.L., Hole D.J., McMurray J.J. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart. 2001;86:516-21. doi:10.1136/heart.86.5.516.; Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-5. doi:10.1001/jama.285.18.2370.; Miyasaka Y., Barnes M.E., Gersh B.J., et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119-25. doi:10.1161/CIRCULATIONAHA.105.595140; Heeringa J., van der Kuip D.A., Hofman A., et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949-53. doi:10.1093/eurheartj/ehi825.; Naccarelli G.V., Varker H., Lin J., Schulman K.L. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104:1534-9. doi:10.1016/j.amjcard.2009.07.022.; Lloyd‐Jones D.M., Wang T.J., Leip E.P., et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110:1042-6. doi:10.1161/01.CIR.0000140263.20897.42; Kirchhof P., Benussi S., Kotecha D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962. doi:10.1093/ejcts /ezw313.; Lip G.Y., Tse H.F., Lane D.A. Atrial fibrillation. Lancet. 2012;379:648-61. doi:10.1016/S0140- 6736(11)61514-6.; Ringborg A., Nieuwlaat R., Lindgren P., et al. Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace. 2008;10:403-11. doi:10.1093/europace/eun048.; Wolowacz S.E., Samuel M., Brennan V.K., et al. The cost of illness of atrial fibrillation: a systematic review of the recent literature. Europace. 2011;13:1375-85. doi:10.1093/europace/eur194.; Rubanenko O.A. Comorbid pathology in patients with atrial fibrillation. Izvestiya Samarskogo Nauchnogo Centra Rossijskoj Akademii Nauk. 2015;17(2):367-70. (In Russ.) [Рубаненко О.А. Коморбидная патология у пациентов с фибрилляцией предсердий. Известия Самарского Научного Центра Российской Академии Наук. 2015;17(2):367-70].; Ballyuzek M.F., Aleksandrova L. N. Frequency and features of the course of ischemic heart disease associated with the development of atrial fibrillation. Vestnik Sankt-Peterburgskogo Universiteta. 2012;11(2):3-9. (In Russ.) [Баллюзек М.Ф., Александрова Л. Н. Частота и особенности течения ишемической болезни сердца, ассоциированной с развитием фибрилляции предсердий. Вестник Санкт-Петербургского Университета. 2012; 11(2):3-9].; Lip G.Y., Laroche C., Dan G.A., et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace. 2014;16(3):308-19. doi:10.1093/europace/eut373.; Dorian P., Guerra P.G., Kerr C.R., et al. Validation of a new simple scale to measure symptoms inatrial fibrillation: the Canadian Cardiovascular Society Severity in Atrial Fibrillation scale. Circ Arrhythm Electrophysiol. 2009; 2: 218-224.doi:10.1161/CIRCEP.108.812347.; Cho J.R., Angiolillo D.J. Percutaneous coronary intervention and atrial fibrillation: The triple therapy dilemma. J Thromb Thrombolysis. 2015;39:203-8. doi:10.1007/s11239-014-1132-z); Valgimigli M., Bueno H., Byrne R.A., et al.; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213-60. doi:10.1093/eurheartj/ehx419.; Lip G., Windecker S., Huber K., et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS) Eur Heart J. 2014; 35(45):3155-79. doi:10.1093/eurheartj/ehu298.; Heidbuchel H., Verhamme P., Alings M., et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467-507. doi:10.1093/europace/euv309.; Napalkov D.A., Sokolova A.A., Rodionov A.V. Atrial fibrillation and ischemic heart disease: how to combine antiplatelet and anticoagulant therapy, depending on the clinical situation? Rational Pharmacotherapy in Cardiology. 2016;12(21):191-5. (In Russ.) [Напалков Д.А., Соколова А.А., Родионов А.В. Фибрилляция предсердий и ишемическая болезнь сердца: как сочетать антиагрегантную и антикоагулянтную терапию в зависимости от клинической ситуации? Рациональная Фармакотерапия в Кардиологии. 2016;12(2):191-5]. doi:10.20996/1819- 6446-2016-12-2-191-195.; Connolly S.J., Ezekowitz M.D., Yusuf S., et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. doi:10.1056/NEJMoa0905561.; Patel M.R., Mahaffey K.W., Garg J., et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.N Engl J Med. 2011;365(10):883-91. doi:10.1056/NEJMoa1009638.; Granger C. B., Alexander J. H., McMurray J. J., et al.; ARISTOTLE Committees and Investigators.Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. doi:10.1056/NEJMoa1107039.; Napalkov D.A., Sokolova A.A. Algorithm for individual selection of a new oral anticoagulant in patients with non-valvular atrial fibrillation based on the available evidence base.EHffektivnayafarmakoterapiya. Kardiologiya I Angiologiya. 2015;2:25-30. (In Russ.) [Напалков Д.А., Соколова А.А. Алгоритм индивидуального выбора нового перорального антикоагулянта у пациентов с неклапанной фибрилляцией предсердий на основе имеющейся доказательной базы. Эффективная фармакотерапия. Кардиология и Ангиология. 2015;2:25-30].; Bahit M. C., Lopes R. D., Wojdyla D. M et al. Apixabanin patients with atrial fibrillation and prior coronary artery disease:insights from the ARISTOTLE trial. Int J Cardiol. 2013;170(2):215-20. doi:10.1016/j.ijcard.2013.10.062.; Rao M.P., Pokorney S.D., Granger C.B. Atrial fibrillation: a review of recent studies with the focus on thosefrom the duke clinical research institute. Scientifica (Cairo). 2014;2014:901586. doi:10.1155/2014/901586.; Alexander J. H., Lopes R. D., Thomas L., et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation:insights from the ARISTOTLE trial. Eur Heart J. 2014;35(4):224-32. doi:10.1093/eurheartj/eht445.; Chugh S.S., Havmoeller R., Narayanan K., et al. Worldwide epidemiology of atrial fibrillation:a Global Burden of Disease 2010 Study. Circulation. 2014;129:837-47. doi:10.1161/CIRCULATIONAHA.113.005119.; Fowkes F.G., Rudan D., Rudan I., et al. Comparison of globalestimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382:1329-40. doi:10.1016/S0140-6736(13)61249-0.; Gage B.F., van Walraven C., Pearce L., et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004;110:2287-92. doi:10.1161/01.CIR.0000145172.55640.93.; Goto S, Bhatt DL, Röther J, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J. 2008;156:855-863.DOI: https://doi.org/10.1016/j.ahj.2009.03.002; Winkel T.A., Hoeks S.E., Schouten O., et al. Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: data from the reduction of atherothrombosis for continued health (REACH) registry. Eur J Vasc Endovasc Surg. 2010;40:9-16. doi:10.1016/j.ejvs.2010.03.003.; Hu P.T., Lopes R.D., Stevens S.R., et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial.J Am Heart Assoc. 2017;6(1):pii:e004699. doi:10.1161/JAHA.116.004699.; Pol T., Held C., Westerbergh J., Lindbäck J., et al. Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial. J Am Heart Assoc. 2018;7(3):pii:e007444. doi:10.1161/JAHA.117.007444.; https://www.rpcardio.com/jour/article/view/1701

Availability: https://www.rpcardio.com/jour/article/view/1701
https://doi.org/10.20996/1819-6446-2018-14-3-441-450

THROMBOSIS OF LEFT ATRIAL APPENDAGE DURING THERAPY WITH DIRECT ORAL ANTICOAGULANT. CLINICAL CASE ; КЛИНИЧЕСКОЕ НАБЛЮДЕНИЕ ТРОМБОЗА УШКА ЛЕВОГО ПРЕДСЕРДИЯ, ВОЗНИКШЕГО НА ФОНЕ ТЕРАПИИ ПРЯМЫМ ПЕРОРАЛЬНЫМ АНТИКОАГУЛЯНТОМ

Authors: I. Daaboul S., S. Koroleva Yu., A. Kudrjavtseva A., A. Sokolova A., D. Napalkov A., V. Fomin V., И. Даабуль С., С. Королева Ю., А. Кудрявцева А., А. Соколова А., Д. Напалков А., В. Фомин В.

Source: Rational Pharmacotherapy in Cardiology; Vol 14, No 3 (2018); 350-355 ; Рациональная Фармакотерапия в Кардиологии; Vol 14, No 3 (2018); 350-355 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2018-14-3

Subject Terms: atrial fibrillation nonvalvular etiology, direct oral anticoagulants, apixaban, dabigatran, left atrial appendage thrombosis, фибрилляция предсердий неклапанной этиологии, прямые пероральные антикоагулянты, апиксабан, дабигатран, тромбоз ушка левого предсердия

File Description: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/1689/1651; Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. doi:10.1056/NEJMoa0905561.; Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91. doi:10.1056/NEJMoa1009638 .; Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. doi:10.1056/NEJMoa1107039.; Giugliano R.P., Ruff C.T., Braunwald E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-104. doi:10.1056/NEJMoa1310907.; Elliott P.M., Anastasakis A., Borger M.A., et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. EurHeartJ. 2014;35(39):2733-79. doi:10.1093/eurheartj/ehu284.; Heidbuchel H., Verhamme P., Alings M., et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467-507. doi:10.1093/europace/euv309.; MacIntyre C., Lakdawala N.K. Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation. 2016;133(19): 1901-5. doi:10.1161/CIRCULATIONAHA.115.015085.; Guttmann O.P., Pavlou M., O'Mahony C., et al. Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA). Eur J Heart Fail. 2015;17(8):837-45. doi:10.1002/ejhf.316.; January C.T., Wann L.S., Alpert J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1-76. doi:10.1161/CIR.0000000000000041.; Szegedi N., Gellér L., Tahin T., et al. Successful direct thrombin inhibitor treatment of a left atrial appendage thrombus developed under rivaroxaban therapy. Orv Hetil. 2016;157(4):154-6. doi:10.1556/650.2016.30350.; De Caterina R., Lip GYH. The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review. Clin Res Cardiol. 2017;106(8):565-572. doi:10.1007/s00392-017-1102-5.; Watanabe T., Shinoda Y., Ikeoka K., et al. Dabigatran Therapy Resulting in the Resolution of Rivaroxaban-resistant Left Atrial Appendage Thrombi in Patients with Atrial Fibrillation. Intern Med. 2017. 56(15):1977-80. doi:10.2169/internalmedicine.56.8508.; Al-Saady N.M., Obel O.A., Camm A.J. Left atrial appendage: structure, function, and role in thromboembolism. Heart. 1999. 82(5):547-54. doi:10.1136/hrt.82.5.547.; Ellis K., Ziada K.M., Vivekananthan D., et al. Transthoracic echocardiographic predictors of left atrial appendage thrombus. Am J Cardiol. 2006. 97(3):421-5. doi:10.1016/j.amjcard.2005.08.065.; Tsai L.M., Lin L.J., Teng J.K., Chen J.H. Prevalence and clinical significance of left atrial thrombus in nonrheumatic atrial fibrillation. Int J Cardiol. 1997;58(2):163-9. doi:10.1016/S016715273(96)02862-8.; Ayirala S., Kumar S., O'Sullivan D.M., Silverman D.I. Echocardiographic predictors of left atrial appendage thrombus formation. J Am Soc Echocardiogr. 2011. 24(5):499-505. doi:10.1016/j.echo.2011.02.010.; Nagarakanti R., Ezekowitz M.D., Oldgren J., et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011. 123(2):131-6. doi:10.1161/CIRCULATIONAHA.110.977546.; Flaker G., Lopes R.D., Al-Khatib S.M., et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014;63(11):1082-7. doi:10.1016/j.jacc.2013.09.062.; Piccini J.P., Stevens S.R., Lokhnygina Y., et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol. 2013. 61(19):1998-2006. doi:10.1016/j.jacc.2013.02.025.; Mitamura H., Nagai T., Watanabe A., et al. Left atrial thrombus formation and resolution during dabigatran therapy: A Japanese Heart Rhythm Society report. J Arrhythm. 2015;31(4):226-31. doi:10.1016/j.joa.2014.12.010.; Morita S., Ajiro Y., Uchida Y., Iwade K. Dabigatran for left atrial thrombus. Eur Heart J. 2013;34(35):2745. doi:10.1093/eurheartj/eht148.; Vidal A., Vanerio G. Dabigatran and left atrial appendage thrombus. J Thromb Thrombolysis. 2012;34(4):545-7. doi:10.1007/s11239-012-0747-1.; Qazi A.H., Wimmer A.P., Huber K.C., et al. Resolution (and Late Recurrence) of WATCHMAN Device-Related Thrombus Following Treatment with Dabigatran. Echocardiography. 2016;33(5):7921795. doi:10.1111/echo.13174.; Tabata E., Yasaka M., Wakugawa Y., et al. Increase in the Size of an Intracardiac Thrombus during Dabigatran Therapy (110 mg b.i.d.) in an Acute Cardioembolic Stroke Patient. Cerebrovasc Dis Extra. 2013;3(1):78-80. doi:10.1159/000351137.; Wyrembak J., Campbell K.B., Steinberg B.A., et al. Incidence and Predictors of Left Atrial Appendage Thrombus in Patients Treated With Nonvitamin K Oral Anticoagulants Versus Warfarin Before Catheter Ablation for Atrial Fibrillation. Am J Cardiol. 2017;119(7):1017-1022. doi:10.1016/j.amjcard.2016.12.008.; Camm A.J., Kirchhof P., Lip G.Y., et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12(10):1360-420. doi:10.1093/europace/euq350.; Hammerstingl C., Pötzsch B., Nickenig G. Resolution of giant left atrial appendage thrombus with rivaroxaban. Thromb Haemost. 2013;109(4):583-4. doi:10.1160/TH12-11-0821.; Dobashi S., Fujino T., Ikeda T. Use of apixaban for an elderly patient with left atrial thrombus. BMJ Case Rep. 2014. pii: bcr2014203870. 2014. doi:10.1136/bcr-2014-203870.; Kawakami T., Kobayakawa H., Ohno H., et al. Resolution of left atrial appendage thrombus with apixaban. Thromb J. 2013. 11(1):26. doi:10.1186/1477-9560-11-26.; Takasugi J., Yamagami H., Okata T., et al. Dissolution of the left atrial appendage thrombus with rivaroxaban therapy. Cerebrovasc Dis. 2013;36(4):322-3. doi:10.1159/000354315.; Vaquerizo B., Sami M. Left Atrial Appendage Thrombus Resolution with Reduced Dose Apixaban. J Atr Fibrillation. 2015;8(1):1182. doi:10.4022/jafib.1182.; Eftekhari A., Damgaard D., Grove E.L. Fatal stroke following treatment with apixaban in a patient with atrial fibrillation and left atrial appendage thrombus. Int J Cardiol. 2016;214:131-2. doi:10.1016/j.ijcard.2016.03.147.; Ohyagi M., Nakamura K., Watanabe M., Fujigasaki H. Embolic stroke during apixaban therapy for left atrial appendage thrombus. J Stroke Cerebrovasc Dis. 2015;24(4):e101-2. doi:10.1016/j.jstrokecerebrovasdis.2014.11.031.; Miwa Y., Minamishima T., Sato T., et al. Resolution of a warfarin and dabigatran-resistant left atrial appendage thrombus with apixaban. J Arrhythm. 2016;32(3):233-5. doi:10.1016/ j.joa.2016.01.009.; Koyama T., Otsuka Y., Kawahara M., et al. A left atrial appendage thrombus that developed during prophylactic low-dose dabigatran treatment resolved after switching to apixaban. Clin Case Rep. 2017;5(5):711-3. doi:10.1002/ccr3.933.; Nagamoto Y., Shiomi T., Sadamatsu K. Thrombolytic action of dabigatran in patients with acute preexisting atrial thrombus. Europace. 2013;15(11):1608. doi:10.1093/europace/eut096.; Lee C.L., Wang H.H., Tsao H.M. The antithrombotic effect of dabigatran. Can J Cardiol. 2014;30(2):248.e1-2. doi:10.1016/j.cjca.2013.09.028.; Santangelo G., Ielasi A., Antonio Scopelliti P., et al. Apixaban-Induced Resolution of A Massive Left Atrial and Appendage Thrombosis in a Very Elderly Patient. J Atr Fibrillation. 2016;9(4):1509. doi:10.4022/jafib.1509.; Li Y., Lin J., Peng C. Resolution of massive left atrial appendage thrombi with rivaroxaban before balloon mitral commissurotomy in severe mitral stenosis: A case report and literature review. Medicine (Baltimore). 2016;95(49):e5577. doi:10.1097/MD.0000000000005577.; Ferner M., Wachtlin D., Konrad T., et al. Rationale and design of the RE-LATED AF--AFNET 7 trial: REsolution of Left atrial-Appendage Thrombus--Effects of Dabigatran in patients with Atrial Fibrillation. Clin Res Cardiol. 2016;105(1):29-36. doi:10.1007/s00392-015-0883-7.; Lip G.Y., Hammerstingl C., Marin F., et al. Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observationalregistry providing baseline data (CLOT-AF). Am Heart J. 2016;178:126-34. doi:10.1016/j.ahj.2016.05.007.; Bernhardt P., Schmidt H., Hammerstingl C., et al. Fate of left atrial thrombi in patients with atrial fibrillation determined by transesophageal echocardiography and cerebral magnetic resonance imaging. Am J Cardiol. 2004;94(6):801-4. doi:10.1016/j.amjcard.2004.06.010.; https://www.rpcardio.com/jour/article/view/1689

Availability: https://www.rpcardio.com/jour/article/view/1689
https://doi.org/10.20996/1819-6446-2018-14-3-350-355

Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease ; Возможности современной антикоагулянтной терапии у пациентов с неклапанной этиологией фибрилляции предсердий и хронической болезнью почек

Authors: I. Daabul S., A. Sokolova A., D. Napalkov A., И. Даабуль С., А. Соколова А., Д. Напалков А.

Source: Rational Pharmacotherapy in Cardiology; Vol 12, No 5 (2016); 595-602 ; Рациональная Фармакотерапия в Кардиологии; Vol 12, No 5 (2016); 595-602 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2016-12-5

Subject Terms: nonvalvular atrial fibrillation, chronic kidney disease, warfarin, direct oral anticoagulants, dabigatran, rivaroxaban, apixaban, renal arteries atherosclerosis, фибрилляция предсердий неклапанной этиологии, хроническая болезнь почек, варфарин, прямые пероральные антикоагулянты, дабигатран, ривароксабан, апиксабан, атеросклероз почечных артерий

File Description: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/1342/1385; Zoni-Berisso M., Lercari F., Carazza T., et al. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 2014; 6: 213-20.; National guidelines on the diagnosis and treatment of atrial fibrillation (2012). Available at: http://www.scardio.ru/content/Guidelines/FP_rkj_13.pdf. Retrieved 09/18/2016. In Russian (Национальные рекомендации по диагностике и лечению фибрилляции предсердий (2012). Доступно на: http://www.scardio.ru/content/Guidelines/FP_rkj_13.pdf.Проверено 18.09.2016).; Smirnov AV, Shilov EM, Dobronravov VA National guidelines. Chronic kidney disease: the basic principles of screening, diagnosis, prevention and treatment approaches. St. Petersburg: Levsha; 2012. In Russian (Смирнов А. В., Шилов Е. М., Добронравов В. А. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. СПб.: Левша: 2012).; Schwartzenberg, S., Lev EI., Sagie A., et al. The Quandary of Oral Anticoagulation in Patients With Atrial Fibrillation and Chronic Kidney Disease. Am J Cardiol 2016; 117(3): 477- 82.; Alonso A., Lopez FL., Matsushita K., et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011; 123(25): 2946-53.; Wheeler D.S., Giugliano R.P., Rangaswami J. Anticoagulation-related nephropathy. Thromb Haemost 2016; 14(3): 461-67.; Sardar P. Chatterjee S., Herzog E., et al. Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials. Can J Cardiol 2014; 30(8): 888-97.; Schurgers L.J., Aebert H., Vermeer C., et al. Oral anticoagulant treatment: friend or foe in cardiovascular disease? Blood 2004; 104(10): 3231-2.; Pankratov V., Pigarova EA, Dzeranova L. K. Vitamin K-dependent proteins: osteocalcin, the Gla-protein matrix and vnekostnye effects. Ozhirenie i Metabolizm 2013; (2): 11-8. In Russian (Панкратова Ю. В., Пигарова Е. А., Дзеранова Л. К. Витамин К-зависимые белки: остеокальцин, матриксный Gla-белок и их внекостные эффекты. Ожирение и метаболизм 2013; (2): 11 - 8).; Luo G., Ducy P., McKee MD., et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386(6620): 78-81.; Price P.A., Faus S.A., Williamson M.K. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998; 18(9): 1400-7.; Koos R., Mahnken AH., Mühlenbruch G., et al. Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. Am J Cardiol 2005; 96(6): 747-9.; Weijs B., Blaauw Y., Rennenberg RJ., et al. Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients. Eur Heart J 2011; 32(20): 2555-62.; Chatrou M.L., Winckers K., Hackeng TM., et al. Vascular calcification: the price to pay for anticoagulation therapy with vitamin K-antagonists. Blood Rev 2012; 26(4): 155-66.; Braam L.A., Hoeks AP., Brouns F., et al. Beneficial effects of vitamins D and K on the elastic properties of the vessel wall in postmenopausal women: a follow-up study. Thromb Haemost 2004; 91(2): 373-80.; Connolly S.J., Ezekowitz MD., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361(12): 1139-51.; Patel M.R., Mahaffey KW., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365(10): 883-91.; Granger C.B., Alexander JH., McMurray JJ., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365(11): 981-92.; Heidbuchel H., Verhamme P., Alings M., et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17(10): 1467-507.; Hijazi Z., Hohnloser SH., Oldgren J., et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014; 129(9): 961-70.; Böhm M., Ezekowitz MD., Connolly SJ., et al. Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. J Am Coll Cardiol 2015; 65(23): 2481-93.; Sparkenbaugh E.M., Chantrathammachart P., Mickelson J., et al. Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood 2014; 123(11): 1747-56.; Lee I.O., Kratz MT., Schirmer SH., et al. The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient mice. J Pharmacol Exp Ther 2012; 343(2): 253-7.; Preusch M.R., Ieronimakis N., Wijelath ES., et al. Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice. Drug Des Devel Ther 2015; 9: 5203-11.; Hara T., Fukuda D., Tanaka K., et al. Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice. Atherosclerosis 2015; 242(2): 639-46.; Landray M.J., Wheeler DC., Lip GY., et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis 2004; 43(2): 244-53.; Brodsky S.V., Nadasdy T., Rovin BH., et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int 2011; 80(2): 181-9.; Brodsky S.V., Collins M., Park E., et al. Warfarin therapy that results in an International Normalization Ratio above the therapeutic range is associated with accelerated progression of chronic kidney disease. Nephron Clin Pract 2010; 115(2): 142-6.; Fox K.A., Piccini JP., Wojdyla D., et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J, 2011; 32(19): 2387-94.; Eto M., Barandiér C., Rathgeb L., et al. Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase. Circ Res 2001; 89(7): 583-90.; Zhou, Q., Bea F., Preuschet M., al. Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. Mediators Inflamm 2011; 2011: 432080.; Mega J.L., Braunwald E., Wiviott SD., et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366(1): 9-19.; Hohnloser S.H., Hijazi Z., Thomas L., et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012; 33(22): 2821-30.; Esmon C.T. Targeting factor Xa and thrombin: impact on coagulation and beyond. Thromb Haemost 2014; 111(4): 625-33.; https://www.rpcardio.com/jour/article/view/1342

Availability: https://www.rpcardio.com/jour/article/view/1342
https://doi.org/10.20996/1819-6446-2016-12-5-595-602

Место и роль ривароксабана у пациентов с фибрилляцией предсердий

Subject Terms: фибрилляция предсердий, ривароксабан, инсульт, atrial fibrillation, прямые пероральные антикоагулянты, stroke, direct oral anticoagulants, rivaroxaban, 3. Good health